benzofurochromene - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	benzofurochromene	go back to main search page
Accession:	CHEBI:38834	browse the term
Definition:	An organic heteropolycyclic compound whose skeleton consists of a chromene ring fused onto a 1-benzofuran ring, together with their substituted derivatives.
Synonyms:	related_synonym:	benzofurochromenes

show annotations for term's descendants Sort by:
Rat (1782) Mouse (1785) Human (1828) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (1782)

coumestrol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 6430548M08 gene like

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KIAA0513 mRNA
Coumestrol results in decreased expression of KIAA0513 mRNA

NCBI chr19:48,168,651...48,216,571
Ensembl chr19:48,198,209...48,216,575

G

aladin WD repeat nucleoporin

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AAAS mRNA
Coumestrol results in increased expression of AAAS mRNA

NCBI chr 7:133,464,315...133,483,961
Ensembl chr 7:133,464,315...133,483,961

G

alanyl-tRNA synthetase 1

increases expression

Coumestrol results in increased expression of AARS1 mRNA

NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147

G

4-aminobutyrate aminotransferase

increases expression

Coumestrol results in increased expression of ABAT mRNA

NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835

G

ATP binding cassette subfamily C member 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABCC5 mRNA

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily D member 3

decreases expression

Coumestrol results in decreased expression of ABCD3 mRNA

NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020

G

ATP binding cassette subfamily E member 1

increases expression

Coumestrol results in increased expression of ABCE1 mRNA

NCBI chr19:28,205,566...28,230,489
Ensembl chr19:28,205,555...28,230,489

G

ATP binding cassette subfamily F member 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ABCF1 mRNA
Coumestrol results in increased expression of ABCF1 mRNA

NCBI chr20:2,802,519...2,815,433
Ensembl chr20:2,802,488...2,815,433

G

ATP binding cassette subfamily G member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABCG1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

abhydrolase domain containing 11

decreases expression
multiple interactions

Coumestrol results in decreased expression of ABHD11 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABHD11 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ABHD11 mRNA

NCBI chr12:21,682,206...21,685,331
Ensembl chr12:21,682,202...21,685,398

G

abhydrolase domain containing 12, lysophospholipase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ABHD12 mRNA

NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564

G

abhydrolase domain containing 16A, phospholipase

decreases expression

Coumestrol results in decreased expression of ABHD16A mRNA

NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927

G

abl-interactor 1

decreases expression

Coumestrol results in decreased expression of ABI1 mRNA

NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792

G

abraxas 1, BRCA1 A complex subunit

decreases expression

Coumestrol results in decreased expression of ABRAXAS1 mRNA

NCBI chr14:8,796,281...8,810,625
Ensembl chr14:8,796,266...8,810,622

G

acetyl-CoA acyltransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA acetyltransferase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACAT2 mRNA
Coumestrol results in increased expression of ACAT2 mRNA

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

acyl-CoA binding domain containing 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACBD3 mRNA

NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380

G

atypical chemokine receptor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACKR3 mRNA

NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237

G

ATP citrate lyase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACLY mRNA
Coumestrol results in increased expression of ACLY mRNA

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

G

acyl-CoA thioesterase 4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACOT4 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ACOT4 mRNA
Coumestrol results in increased expression of ACOT4 mRNA

NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917

G

acyl-CoA thioesterase 7

increases expression
multiple interactions

Coumestrol results in increased expression of ACOT7 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACOT7 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ACOT7 mRNA

NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309

G

acyl-CoA synthetase long-chain family member 3

decreases expression

Coumestrol results in decreased expression of ACSL3 mRNA

NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627

G

acyl-CoA synthetase short-chain family member 3

decreases expression

Coumestrol results in decreased expression of ACSS3 mRNA

NCBI chr 7:42,241,261...42,450,209
Ensembl chr 7:42,242,652...42,450,230

G

activin A receptor type 1

decreases expression

Coumestrol results in decreased expression of ACVR1 mRNA

NCBI chr 3:42,978,558...43,097,892
Ensembl chr 3:42,978,561...43,098,241

G

acylphosphatase 1

increases expression
multiple interactions

Coumestrol results in increased expression of ACYP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACYP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ACYP1 mRNA

NCBI chr 6:104,919,162...104,932,348
Ensembl chr 6:104,919,162...104,932,387

G

adenosine deaminase, tRNA-specific 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ADAT1 mRNA

NCBI chr19:39,918,083...39,956,886
Ensembl chr19:39,918,227...39,956,883

G

adducin 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ADD3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ADD3 mRNA
Coumestrol results in increased expression of ADD3 mRNA

NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124

G

adenosine kinase

increases expression

Coumestrol results in increased expression of ADK mRNA

NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510

G

adrenoceptor alpha 2A

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA]

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

actin filament associated protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AFAP1 mRNA

NCBI chr14:74,743,322...74,856,300
Ensembl chr14:74,743,320...74,856,263

G

ALF transcription elongation factor 4

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AFF4 mRNA
Coumestrol results in decreased expression of AFF4 mRNA

NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751

G

alpha-fetoprotein

affects binding

Coumestrol binds to AFP protein

PMID:23013281 PMID:25349334

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 1

decreases expression

Coumestrol results in decreased expression of AGAP1 mRNA

NCBI chr 9:90,039,720...90,475,196
Ensembl chr 9:90,039,605...90,470,958

G

argonaute RISC catalytic component 2

decreases expression

Coumestrol results in decreased expression of AGO2 mRNA

NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974

G

1-acylglycerol-3-phosphate O-acyltransferase 3

decreases expression

Coumestrol results in decreased expression of AGPAT3 mRNA

NCBI chr20:10,330,960...10,415,358
Ensembl chr20:10,384,507...10,415,358

G

anterior gradient 2, protein disulphide isomerase family member

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AGR2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AGR2 mRNA
Coumestrol results in increased expression of AGR2 mRNA

NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371

G

anterior gradient 3, protein disulphide isomerase family member

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AGR3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AGR3 mRNA
Coumestrol results in increased expression of AGR3 mRNA

NCBI chr 6:52,643,391...52,666,638
Ensembl chr 6:52,643,391...52,666,638

G

angiotensin II receptor-associated protein

increases expression

Coumestrol results in increased expression of AGTRAP mRNA

NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036

G

adenosylhomocysteinase-like 1

decreases expression

Coumestrol results in decreased expression of AHCYL1 mRNA

NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815

G

activator of Hsp90 ATPase activity 1

increases expression

Coumestrol results in increased expression of AHSA1 mRNA

NCBI chr 6:106,913,296...106,921,347
Ensembl chr 6:106,913,530...106,921,345

G

ajuba LIM protein

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AJUBA mRNA
Coumestrol results in decreased expression of AJUBA mRNA

NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021

G

A-kinase anchoring protein 13

decreases expression
multiple interactions

Coumestrol results in decreased expression of AKAP13 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AKAP13 mRNA

NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646

G

activated leukocyte cell adhesion molecule

decreases expression

Coumestrol results in decreased expression of ALCAM mRNA

NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954

G

aldehyde dehydrogenase 16 family, member A1

increases expression

Coumestrol results in increased expression of ALDH16A1 mRNA

NCBI chr 1:95,626,727...95,639,808
Ensembl chr 1:95,613,558...95,640,131

G

aldehyde dehydrogenase 3 family, member B2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of ALDH3B2 mRNA
Coumestrol results in decreased expression of ALDH3B2 mRNA

NCBI chr 1:201,250,260...201,264,699
Ensembl chr 1:201,253,157...201,264,705

G

aldehyde dehydrogenase 3 family, member B3

multiple interactions
decreases expression

[Coumestrol co-treated with Resveratrol] results in decreased expression of ALDH3B2 mRNA
Coumestrol results in decreased expression of ALDH3B2 mRNA

NCBI chr 1:201,193,832...201,201,666
Ensembl chr 1:201,187,962...201,250,204

G

aldehyde dehydrogenase 4 family, member A1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of ALDH4A1 mRNA

NCBI chr 5:151,880,002...151,905,491
Ensembl chr 5:151,830,701...151,925,345

G

ALG6, alpha-1,3-glucosyltransferase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ALG6 mRNA
Coumestrol results in increased expression of ALG6 mRNA

NCBI chr 5:114,404,972...114,454,440
Ensembl chr 5:114,405,010...114,454,439

G

ALG8, alpha-1,3-glucosyltransferase

increases expression
multiple interactions

Coumestrol results in increased expression of ALG8 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ALG8 mRNA

NCBI chr 1:151,684,344...151,704,310
Ensembl chr 1:151,684,396...151,704,302

G

alkB homolog 7

decreases expression

Coumestrol results in decreased expression of ALKBH7 mRNA

NCBI chr 9:1,838,886...1,841,044
Ensembl chr 9:1,838,811...1,841,044

G

alkaline phosphatase, biomineralization associated

multiple interactions

[Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein; fulvestrant inhibits the reaction [[Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein]

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

alsin Rho guanine nucleotide exchange factor ALS2

decreases expression

Coumestrol results in decreased expression of ALS2 mRNA

NCBI chr 9:60,613,182...60,686,394
Ensembl chr 9:60,613,167...60,670,737

G

Aly/REF export factor

increases expression

Coumestrol results in increased expression of ALYREF mRNA

NCBI chr10:105,871,424...105,875,076
Ensembl chr10:105,871,306...105,875,069

G

adenosylmethionine decarboxylase 1

increases expression
multiple interactions

Coumestrol results in increased expression of AMD1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AMD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AMD1 mRNA

NCBI chr20:43,695,783...43,711,476
Ensembl chr20:43,697,237...43,711,476

G

autocrine motility factor receptor

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of AMFR mRNA

NCBI chr19:10,996,705...11,032,260
Ensembl chr19:10,996,099...11,032,247

G

AMMECR nuclear protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AMMECR1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AMMECR1 mRNA
Coumestrol results in increased expression of AMMECR1 mRNA

NCBI chr X:106,465,982...106,571,382
Ensembl chr X:106,466,699...106,571,487

G

angiomotin like 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of AMOTL2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AMOTL2 mRNA

NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910

G

anaphase-promoting complex subunit 5

increases expression

Coumestrol results in increased expression of ANAPC5 mRNA

NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781

G

anaphase promoting complex subunit 7

increases expression

Coumestrol results in increased expression of ANAPC7 mRNA

NCBI chr12:34,131,214...34,160,819
Ensembl chr12:34,133,429...34,160,005

G

anillin, actin binding protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANLN mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ANLN mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA]
Coumestrol results in increased expression of ANLN mRNA

PMID:18310284 PMID:19167446

NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538

G

anoctamin 6

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANO6 mRNA
Coumestrol results in decreased expression of ANO6 mRNA

NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589

G

acidic nuclear phosphoprotein 32 family member A

increases expression

Coumestrol results in increased expression of ANP32A mRNA

NCBI chr 8:62,829,099...62,865,443
Ensembl chr 8:62,827,456...62,865,443

G

acidic nuclear phosphoprotein 32 family member E

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANP32E mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ANP32E mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA]
Coumestrol results in increased expression of ANP32E mRNA

PMID:18310284 PMID:19167446

NCBI chr 2:183,472,600...183,489,057
Ensembl chr 2:183,472,609...183,489,054

G

annexin A2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

annexin A3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANXA3 mRNA

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

annexin A9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANXA9 mRNA

NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374

G

adaptor related protein complex 1 subunit beta 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AP1B1 mRNA

NCBI chr14:79,879,482...79,930,778
Ensembl chr14:79,879,533...79,930,778

G

adaptor related protein complex 1 subunit mu 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AP1M1 mRNA

NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,584,730...17,602,403

G

adaptor related protein complex 2 subunit sigma 1

increases expression

Coumestrol results in increased expression of AP2S1 mRNA

NCBI chr 1:77,417,496...77,428,903
Ensembl chr 1:77,417,477...77,428,905

G

amyloid beta precursor protein binding family B member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of APBB2 mRNA

NCBI chr14:41,557,918...41,878,622
Ensembl chr14:41,557,972...41,877,495

G

apolipoprotein D

decreases expression

Coumestrol results in decreased expression of APOD mRNA

NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305

G

amyloid beta precursor protein

decreases expression

Coumestrol results in decreased expression of APP mRNA

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 3 (Gill blood group)

decreases expression
multiple interactions

Coumestrol results in decreased expression of AQP3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

androgen receptor

decreases expression
multiple interactions

Coumestrol results in decreased expression of AR mRNA
Coumestrol inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein]

PMID:11867264 PMID:29162470

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ADP ribosylation factor guanine nucleotide exchange factor 2

decreases expression

Coumestrol results in decreased expression of ARFGEF2 mRNA

NCBI chr 3:155,547,504...155,633,652
Ensembl chr 3:155,547,538...155,630,856

G

ARFGEF family member 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARFGEF3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ARFGEF3 mRNA
Coumestrol results in decreased expression of ARFGEF3 mRNA

NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084

G

Rho GTPase activating protein 19

increases expression

Coumestrol results in increased expression of ARHGAP19 mRNA

NCBI chr 1:240,571,554...240,617,361
Ensembl chr 1:240,580,871...240,617,287

G

Rho GTPase activating protein 39

decreases expression

Coumestrol results in decreased expression of ARHGAP39 mRNA

NCBI chr 7:108,446,280...108,538,875
Ensembl chr 7:108,446,282...108,538,831

G

Rho GDP dissociation inhibitor alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARHGDIA mRNA

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

Rho guanine nucleotide exchange factor 26

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARHGEF26 mRNA
Coumestrol results in increased expression of ARHGEF26 mRNA

NCBI chr 2:146,740,336...146,850,918
Ensembl chr 2:146,739,631...146,850,819

G

Rho guanine nucleotide exchange factor 37

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARHGEF37 mRNA

NCBI chr18:54,935,256...55,001,017
Ensembl chr18:54,949,110...55,000,669

G

Rho guanine nucleotide exchange factor 39

increases expression

Coumestrol results in increased expression of ARHGEF39 mRNA

NCBI chr 5:57,752,509...57,756,079
Ensembl chr 5:57,752,509...57,756,109

G

AT-rich interaction domain 4B

decreases expression

Coumestrol results in decreased expression of ARID4B mRNA

NCBI chr17:51,138,419...51,262,894
Ensembl chr17:51,138,535...51,262,906

G

ADP ribosylation factor like GTPase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARL3 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ARL3 mRNA

NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820

G

aryl hydrocarbon receptor nuclear translocator

decreases expression

Coumestrol results in decreased expression of ARNT mRNA

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

arrestin domain containing 3

decreases expression

Coumestrol results in decreased expression of ARRDC3 mRNA

NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978

G

aristaless related homeobox

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARX mRNA

NCBI chr X:58,016,233...58,028,149
Ensembl chr X:58,016,233...58,028,142

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of ASAP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ASAP1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ASAP1 mRNA

NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754

G

anti-silencing function 1B histone chaperone

increases expression
multiple interactions

Coumestrol results in increased expression of ASF1B mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ASF1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ASF1B mRNA

NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549

G

assembly factor for spindle microtubules

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ASPM mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ASPM mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA]
Coumestrol results in increased expression of ASPM mRNA

PMID:18310284 PMID:19167446

NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755

G

ATPase family, AAA domain containing 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATAD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ATAD2 mRNA
Coumestrol results in increased expression of ATAD2 mRNA

NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738

G

activating transcription factor 2

increases expression

Coumestrol results in increased expression of ATF2 mRNA

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

activating transcription factor 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATF3 mRNA
Coumestrol results in decreased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

autophagy related 14

decreases expression

Coumestrol results in decreased expression of ATG14 mRNA

NCBI chr15:20,795,750...20,827,113
Ensembl chr15:20,795,750...20,827,113

G

atos homolog A

decreases expression
multiple interactions

Coumestrol results in decreased expression of ATOSA mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATOSA mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of ATOSA mRNA

NCBI chr 8:75,694,828...75,772,565
Ensembl chr 8:75,695,022...75,772,549

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

ATP23 metallopeptidase and ATP synthase assembly factor homolog

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATP23 mRNA
Coumestrol results in increased expression of ATP23 mRNA

NCBI chr 7:62,714,752...62,729,893
Ensembl chr 7:62,714,785...62,729,862

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of ATP2A3 mRNA

NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP2B1 mRNA
Coumestrol results in decreased expression of ATP2B1 mRNA

NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295

G

ATPase secretory pathway Ca2+ transporting 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP2C1 mRNA
Coumestrol results in decreased expression of ATP2C1 mRNA

NCBI chr 8:106,034,777...106,155,854
Ensembl chr 8:106,034,636...106,156,006

G

ATP synthase membrane subunit c locus 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATP5MC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ATP5MC1 mRNA
Coumestrol results in increased expression of ATP5MC1 mRNA

NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124
Ensembl chr10:81,023,925...81,027,124

G

ATPase H+ transporting V0 subunit e1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP6V0E1 mRNA
Coumestrol results in decreased expression of ATP6V0E1 mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

ATPase phospholipid transporting 8B1

decreases expression

Coumestrol results in decreased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

ATPase phospholipid transporting 8B2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of ATP8B2 mRNA
Coumestrol results in decreased expression of ATP8B2 mRNA

NCBI chr 2:175,378,514...175,402,265
Ensembl chr 2:175,378,517...175,401,883

G

ATPase phospholipid transporting 9A (putative)

decreases expression
multiple interactions

Coumestrol results in decreased expression of ATP9A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP9A mRNA

NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818

G

ataxin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATXN1 mRNA

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

aurora kinase A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AURKA mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AURKA mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA]
Coumestrol results in increased expression of AURKA mRNA

PMID:18310284 PMID:19167446

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

aurora kinase B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AURKB mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AURKB mRNA
Coumestrol results in increased expression of AURKB mRNA

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

activator of transcription and developmental regulator AUTS2

decreases expression
multiple interactions

Coumestrol results in decreased expression of AUTS2 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of AUTS2 mRNA

NCBI chr12:24,104,187...25,194,123
Ensembl chr12:24,104,192...25,194,416

G

beta-2 microglobulin

increases expression

Coumestrol results in increased expression of B2M mRNA

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of B3GALNT1 mRNA

NCBI chr 2:153,847,297...153,877,371
Ensembl chr 2:153,846,474...153,877,332

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of B3GNT5 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of B3GNT5 mRNA
Coumestrol results in decreased expression of B3GNT5 mRNA

NCBI chr11:81,141,102...81,153,206
Ensembl chr11:81,140,599...81,156,166

G

beta-secretase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BACE1 mRNA

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

beta-secretase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BACE2 mRNA

NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546

G

BAG cochaperone 2

increases expression
multiple interactions

Coumestrol results in increased expression of BAG2 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of BAG2 mRNA

NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721

G

BAG cochaperone 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BAG3 mRNA
Coumestrol results in decreased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BAG cochaperone 5

decreases expression

Coumestrol results in decreased expression of BAG5 mRNA

NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970

G

BAF nuclear assembly factor 1

increases expression

Coumestrol results in increased expression of BANF1 mRNA

NCBI chr 1:202,672,170...202,674,215
Ensembl chr 1:202,671,305...202,674,188

G

BRCA1 associated RING domain 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BARD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BARD1 mRNA
Coumestrol results in increased expression of BARD1 mRNA

NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265

G

BCL2 associated X, apoptosis regulator

increases expression
affects binding

Coumestrol results in increased expression of BAX protein
Coumestrol binds to BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

bromodomain adjacent to zinc finger domain, 2A

decreases expression

Coumestrol results in decreased expression of BAZ2A mRNA

NCBI chr 7:523,204...560,911
Ensembl chr 7:523,265...560,659

G

Bardet-Biedl syndrome 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of BBS1 mRNA

NCBI chr 1:202,184,812...202,204,118
Ensembl chr 1:202,186,125...202,204,086

G

BCAR3 adaptor protein, NSP family member

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCAR3 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of BCAR3 mRNA

NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798

G

BCAS3, microtubule associated cell migration factor

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of BCAS3 mRNA

NCBI chr10:70,213,710...70,673,080
Ensembl chr10:70,214,098...70,673,080

G

branched chain keto acid dehydrogenase E1 subunit beta

decreases expression

Coumestrol results in decreased expression of BCKDHB mRNA

NCBI chr 8:84,845,264...85,027,812
Ensembl chr 8:84,845,264...85,027,812

G

BCL2, apoptosis regulator

decreases expression
multiple interactions
affects binding

Coumestrol results in decreased expression of BCL2 protein
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BCL2 mRNA
Coumestrol binds to BCL2 protein

PMID:19167446 PMID:20623010 PMID:28986287

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2 like 12

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BCL2L12 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BCL2L12 mRNA
Coumestrol results in increased expression of BCL2L12 mRNA

NCBI chr 1:95,472,272...95,480,991
Ensembl chr 1:95,472,272...95,480,991

G

BCL3, transcription coactivator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCL3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

BCL9, transcription coactivator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCL9 mRNA

NCBI chr 2:184,760,616...184,846,261
Ensembl chr 2:184,760,618...184,786,435

G

BCL9 like

decreases expression

Coumestrol results in decreased expression of BCL9L mRNA

NCBI chr 8:44,811,977...44,840,611
Ensembl chr 8:44,811,977...44,840,611

G

BCL2-associated transcription factor 1

increases expression

Coumestrol results in increased expression of BCLAF1 mRNA

NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832

G

BCLAF1 and THRAP3 family member 3

decreases expression

Coumestrol results in decreased expression of BCLAF3 mRNA

NCBI chr X:35,257,228...35,328,883
Ensembl chr X:35,263,576...35,328,816

G

BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone

increases expression

Coumestrol results in increased expression of BCS1L mRNA

NCBI chr 9:76,164,925...76,168,940
Ensembl chr 9:76,164,932...76,168,938

G

brain expressed X-linked 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BEX2 mRNA

NCBI chr X:99,219,014...99,220,518
Ensembl chr X:99,219,014...99,220,958

G

basic helix-loop-helix family, member e40

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BHLHE40 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BHLHE40 mRNA
Coumestrol results in decreased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

BCL2-interacting killer

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of BIK mRNA

NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296

G

bridging integrator 3

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA]

NCBI chr15:45,173,725...45,212,607
Ensembl chr15:45,173,732...45,212,604

G

baculoviral IAP repeat-containing 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BIRC5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BIRC5 mRNA
Coumestrol results in increased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BLM RecQ like helicase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BLM mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BLM mRNA
Coumestrol results in increased expression of BLM mRNA

NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312

G

B-cell linker

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BLNK mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BLNK mRNA

NCBI chr 1:239,753,640...239,821,113
Ensembl chr 1:239,753,648...239,821,113

G

biogenesis of lysosomal organelles complex 1 subunit 6

decreases expression

Coumestrol results in decreased expression of BLOC1S6 mRNA

NCBI chr 3:109,816,397...109,826,528
Ensembl chr 3:109,816,366...109,828,308

G

bridge-like lipid transfer protein family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BLTP2 mRNA

NCBI chr10:63,155,999...63,185,213
Ensembl chr10:63,156,044...63,191,141

G

biliverdin reductase B

increases expression

Coumestrol results in increased expression of BLVRB mRNA

NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375

G

basic leucine zipper nuclear factor 1

decreases expression

Coumestrol results in decreased expression of BLZF1 mRNA

NCBI chr13:76,641,757...76,656,977
Ensembl chr13:76,641,515...76,656,999

G

bMERB domain containing 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMERB1 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of BMERB1 mRNA
Coumestrol results in decreased expression of BMERB1 mRNA

NCBI chr10:1,779,834...1,946,586
Ensembl chr10:1,779,835...1,946,575

G

Bcl2 modifying factor

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMF mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BMF mRNA
Coumestrol results in decreased expression of BMF mRNA

NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145

G

bone morphogenetic protein 2

multiple interactions

Coumestrol inhibits the reaction [menatetrenone promotes the reaction [Phosphates results in increased expression of BMP2 mRNA]]; Coumestrol inhibits the reaction [menatetrenone results in increased expression of BMP2 mRNA]; Coumestrol inhibits the reaction [menatetrenone results in increased susceptibility to BMP2 protein]; Coumestrol inhibits the reaction [Phosphates promotes the reaction [menatetrenone results in increased expression of BMP2 mRNA]]

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 5

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of BMP5 mRNA

NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925

G

bone morphogenetic protein 7

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMP7 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BMP7 mRNA
Coumestrol results in decreased expression of BMP7 mRNA

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

bone morphogenetic protein receptor type 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMPR2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BMPR2 mRNA

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

BCL2 interacting protein 3 like

decreases expression

Coumestrol results in decreased expression of BNIP3L mRNA

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

bora, aurora kinase A activator

increases expression
multiple interactions

Coumestrol results in increased expression of BORA mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of BORA mRNA

NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322

G

BRCA1-associated ATM activator 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRAT1 mRNA

NCBI chr12:13,928,889...13,951,760
Ensembl chr12:13,928,898...13,941,248

G

BRCA1, DNA repair associated

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BRCA1 mRNA
Coumestrol results in increased expression of BRCA1 mRNA

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

BRCA2, DNA repair associated

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BRCA2 mRNA
Coumestrol results in increased expression of BRCA2 mRNA

NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567

G

bromodomain containing 3

decreases expression

Coumestrol results in decreased expression of BRD3 mRNA

NCBI chr 3:10,773,163...10,829,675
Ensembl chr 3:10,775,272...10,829,577

G

brain protein I3

decreases expression

Coumestrol results in decreased expression of BRI3 mRNA

NCBI chr12:10,341,007...10,364,655
Ensembl chr12:10,341,011...10,364,735

G

Bri3 binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRI3BP mRNA

NCBI chr12:31,176,742...31,188,563
Ensembl chr12:31,173,971...31,188,572

G

bromodomain and WD repeat domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BRWD1 mRNA

NCBI chr11:35,286,364...35,378,768
Ensembl chr11:35,288,313...35,378,768

G

BSD domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BSDC1 mRNA

NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092

G

basigin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BSG mRNA

NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387

G

BTB domain containing 7

decreases expression

Coumestrol results in decreased expression of BTBD7 mRNA

NCBI chr 6:121,920,365...122,010,114
Ensembl chr 6:121,923,023...121,972,405

G

BTG anti-proliferation factor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BTG1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BTG1 mRNA
Coumestrol results in decreased expression of BTG1 mRNA

NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649

G

BTG anti-proliferation factor 2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of BTG2 mRNA
Coumestrol results in decreased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

BUB1 mitotic checkpoint serine/threonine kinase

increases expression
multiple interactions

Coumestrol results in increased expression of BUB1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of BUB1 mRNA

NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650

G

BUB1 mitotic checkpoint serine/threonine kinase B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BUB1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BUB1B mRNA
Coumestrol results in increased expression of BUB1B mRNA

NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547

G

similar to human chromosome 3 open reading frame 52

decreases expression

Coumestrol results in decreased expression of C3ORF52 mRNA

NCBI chr11:55,166,986...55,192,273
Ensembl chr11:55,166,678...55,192,292

G

similar to human chromosome 1 open reading frame 115

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of C1ORF115 mRNA
Coumestrol results in decreased expression of C1ORF115 mRNA

NCBI chr13:96,422,308...96,432,044
Ensembl chr13:96,422,302...96,432,068

G

similar to human chromosome 18 open reading frame 32

decreases expression

Coumestrol results in decreased expression of C18ORF32 mRNA

NCBI chr18:68,586,278...68,594,851
Ensembl chr18:68,586,211...68,596,787

G

similar to human chromosome 9 open reading frame 40

increases expression
multiple interactions

Coumestrol results in increased expression of C9ORF40 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C9ORF40 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of C9ORF40 mRNA

NCBI chr 1:216,128,687...216,132,896
Ensembl chr 1:216,128,651...216,133,045

G

similar to human chromosome 4 open reading frame 3

decreases expression

Coumestrol results in decreased expression of C4ORF3 mRNA

NCBI chr 2:211,055,925...211,057,685
Ensembl chr 2:211,055,911...211,057,681

G

similar to human chromosome 4 open reading frame 46

increases expression
multiple interactions

Coumestrol results in increased expression of C4ORF46 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of C4ORF46 mRNA

NCBI chr 2:164,762,994...164,766,126
Ensembl chr 2:164,762,960...164,766,128

G

similar to human chromosome 5 open reading frame 34

increases expression
multiple interactions

Coumestrol results in increased expression of C5ORF34 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C5ORF34 mRNA

NCBI chr 2:51,553,223...51,577,090
Ensembl chr 2:51,555,432...51,577,085

G

complement C5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C5 mRNA

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

similar to human chromosome 9 open reading frame 152

decreases expression
multiple interactions

Coumestrol results in decreased expression of C9ORF152 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of C9ORF152 mRNA

NCBI chr 5:72,660,573...72,667,941
Ensembl chr 5:72,660,573...72,668,379

G

similar to human chromosome 2 open reading frame 69

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of C2ORF69 mRNA
Coumestrol results in increased expression of C2ORF69 mRNA

NCBI chr 9:58,949,821...58,958,456
Ensembl chr 9:58,949,846...58,958,561

G

calcyclin binding protein

increases expression
multiple interactions

Coumestrol results in increased expression of CACYBP mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CACYBP mRNA

NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177

G

cell adhesion molecule 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CADM1 mRNA
Coumestrol results in decreased expression of CADM1 mRNA

NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833

G

calcitonin receptor

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CALCR mRNA

NCBI chr 4:31,661,270...31,736,392
Ensembl chr 4:31,661,273...31,736,392

G

calmodulin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CALM3 mRNA

NCBI chr 1:77,590,668...77,597,776
Ensembl chr 1:77,589,230...77,592,207

G

calumenin

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CALU mRNA
Coumestrol results in increased expression of CALU mRNA

NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593

G

calcium/calmodulin-dependent protein kinase ID

decreases expression

Coumestrol results in decreased expression of CAMK1D mRNA

NCBI chr17:72,581,899...72,982,704
Ensembl chr17:72,581,979...72,980,556

G

calcium/calmodulin-dependent protein kinase II delta

decreases expression
multiple interactions

Coumestrol results in decreased expression of CAMK2D mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAMK2D mRNA

NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178

G

calcium/calmodulin-dependent protein kinase II inhibitor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAMK2N1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CAMK2N1 mRNA
Coumestrol results in decreased expression of CAMK2N1 mRNA

NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600

G

calcium activated nucleotidase 1

increases expression

Coumestrol results in increased expression of CANT1 mRNA

NCBI chr10:103,637,079...103,650,240
Ensembl chr10:103,531,504...103,650,109

G

carbonic anhydrase 12

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CA12 mRNA

NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440

G

carbonic anhydrase 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CA2 mRNA

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

calcium regulated heat stable protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CARHSP1 mRNA
Coumestrol results in increased expression of CARHSP1 mRNA

NCBI chr10:6,946,036...6,960,556
Ensembl chr10:6,946,959...7,020,019

G

caspase 3

increases expression

Coumestrol results in increased expression of CASP3 protein

PMID:19165469 PMID:28986287

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases expression

Coumestrol results in increased expression of CASP7 protein

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8 associated protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CASP8AP2 mRNA

NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275

G

caspase 9

increases expression

Coumestrol results in increased expression of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

calpastatin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAST mRNA

NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659

G

caveolin 1

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CAV1 mRNA
Coumestrol results in increased expression of CAV1 mRNA

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

core-binding factor subunit beta

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CBFB mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CBFB mRNA
Coumestrol results in increased expression of CBFB mRNA

NCBI chr19:33,049,162...33,092,752
Ensembl chr19:33,049,172...33,092,751

G

Cbl proto-oncogene B

decreases expression
multiple interactions

Coumestrol results in decreased expression of CBLB mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CBLB mRNA

NCBI chr11:48,589,878...48,756,940
Ensembl chr11:48,592,703...48,756,839

G

carbonyl reductase 1

increases expression

Coumestrol results in increased expression of CBR1 mRNA

NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393

G

chromobox 4

decreases expression

Coumestrol results in decreased expression of CBX4 mRNA

NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706

G

chromobox 5

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CBX5 mRNA
Coumestrol results in increased expression of CBX5 mRNA

NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022

G

coiled-coil domain containing 117

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CCDC117 mRNA

NCBI chr14:80,399,236...80,409,824
Ensembl chr14:80,400,294...80,409,659

G

coiled-coil domain containing 14

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCDC14 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCDC14 mRNA

NCBI chr11:66,052,063...66,087,915
Ensembl chr11:66,052,620...66,087,956

G

coiled-coil domain containing 167

increases expression

Coumestrol results in increased expression of CCDC167 mRNA

NCBI chr20:7,763,927...7,782,090
Ensembl chr20:7,751,782...7,781,613

G

coiled-coil domain containing 34

increases expression
multiple interactions

Coumestrol results in increased expression of CCDC34 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCDC34 mRNA

NCBI chr 3:96,553,074...96,588,310
Ensembl chr 3:96,552,992...96,588,146

G

coiled-coil domain containing 47

increases expression

Coumestrol results in increased expression of CCDC47 mRNA

NCBI chr10:91,130,303...91,148,829
Ensembl chr10:91,130,303...91,148,881

G

coiled-coil domain containing 51

increases expression

Coumestrol results in increased expression of CCDC51 mRNA

NCBI chr 8:109,722,595...109,741,478
Ensembl chr 8:109,722,557...109,741,472

G

coiled-coil domain containing 88C

decreases expression

Coumestrol results in decreased expression of CCDC88C mRNA

NCBI chr 6:120,169,752...120,289,459
Ensembl chr 6:120,169,738...120,289,555

G

cellular communication network factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCN5 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CCN5 mRNA; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CCN5 mRNA]

PMID:19167446 PMID:23384675

NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636

G

cyclin A2

decreases expression
increases expression
multiple interactions

Coumestrol results in decreased expression of CCNA2 protein
Coumestrol results in increased expression of CCNA2 protein
[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA]

PMID:18310284 PMID:20623010

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNB1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCNB1 mRNA
Coumestrol results in increased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin B2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNB2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCNB2 mRNA
Coumestrol results in increased expression of CCNB2 mRNA

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

cyclin D1

multiple interactions
increases expression

CCND1 protein promotes the reaction [Coumestrol results in increased activity of ESR1 protein]
Coumestrol results in increased expression of CCND1 mRNA

PMID:16328721 PMID:19800779

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

decreases expression

Coumestrol results in decreased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin E2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNE2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCNE2 mRNA
Coumestrol results in increased expression of CCNE2 mRNA

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cyclin F

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNF mRNA
Coumestrol results in increased expression of CCNF mRNA

NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101

G

cyclin G2

decreases expression

Coumestrol results in decreased expression of CCNG2 mRNA

NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830

G

cyclin I

decreases expression

Coumestrol results in decreased expression of CCNI mRNA

NCBI chr14:14,879,698...14,902,510
Ensembl chr14:14,879,717...14,902,510

G

centriolar coiled-coil protein 110

multiple interactions

[Coumestrol co-treated with Resveratrol] results in increased expression of CCP110 mRNA

NCBI chr 1:173,042,238...173,072,873
Ensembl chr 1:173,042,310...173,072,873

G

cell cycle progression 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CCPG1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CCPG1 mRNA

NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430

G

CD24 molecule

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CD24 mRNA

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

G

CD320 molecule

increases expression

Coumestrol results in increased expression of CD320 mRNA

NCBI chr 7:14,626,171...14,631,976
Ensembl chr 7:14,609,146...14,631,976

G

CD44 molecule

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CD44 mRNA
Coumestrol results in increased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

CD55 molecule (Cromer blood group)

decreases expression
multiple interactions

Coumestrol results in decreased expression of CD55 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CD55 mRNA

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

CD59b molecule

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CD59 mRNA

NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847

G

cell division cycle 14B

decreases expression

Coumestrol results in decreased expression of CDC14B mRNA

NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235

G

cell division cycle 25A

increases expression
multiple interactions

Coumestrol results in increased expression of CDC25A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC25A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC25A mRNA

NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701

G

cell division cycle 25C

increases expression
multiple interactions

Coumestrol results in increased expression of CDC25C mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC25C mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC25C mRNA

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cell division cycle 27

increases expression
multiple interactions

Coumestrol results in increased expression of CDC27 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC27 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC27 mRNA

NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736

G

CDC42 binding protein kinase beta

decreases expression

Coumestrol results in decreased expression of CDC42BPB mRNA

NCBI chr 6:130,333,712...130,416,631
Ensembl chr 6:130,333,712...130,416,377

G

cell division cycle 45

increases expression
multiple interactions

Coumestrol results in increased expression of CDC45 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC45 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CDC45 mRNA

NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle 5-like

increases expression

Coumestrol results in increased expression of CDC5L mRNA

NCBI chr 9:15,564,949...15,603,453
Ensembl chr 9:15,564,767...15,603,450

G

cell division cycle 6

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC6 mRNA
Coumestrol results in increased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cell division cycle 7

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC7 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC7 mRNA
Coumestrol results in increased expression of CDC7 mRNA

NCBI chr14:2,804,660...2,824,796
Ensembl chr14:2,804,661...2,824,778

G

cell division cycle associated 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA2 mRNA
Coumestrol results in increased expression of CDCA2 mRNA

NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611

G

cell division cycle associated 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA3 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA]
Coumestrol results in increased expression of CDCA3 mRNA

PMID:18310284 PMID:19167446

NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799

G

cell division cycle associated 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA4 mRNA

NCBI chr 6:131,892,305...131,901,571
Ensembl chr 6:131,892,087...131,901,564

G

cell division cycle associated 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA5 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CDCA5 mRNA
Coumestrol results in increased expression of CDCA5 mRNA

NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023

G

cell division cycle associated 7 like

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA7L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA7L mRNA
Coumestrol results in increased expression of CDCA7L mRNA

NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888

G

cell division cycle associated 8

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA8 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA8 mRNA
Coumestrol results in increased expression of CDCA8 mRNA

NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629

G

cadherin 12

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDH12 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDH12 mRNA

NCBI chr 2:70,474,679...71,705,369
Ensembl chr 2:70,475,043...71,700,572

G

cyclin-dependent kinase 1

increases expression
multiple interactions

Coumestrol results in increased expression of CDK1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase 13

decreases expression

Coumestrol results in decreased expression of CDK13 mRNA

NCBI chr17:47,251,145...47,344,675
Ensembl chr17:47,251,163...47,341,721

G

cyclin-dependent kinase 17

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PCTK2 mRNA

NCBI chr 7:27,683,890...27,765,814
Ensembl chr 7:27,683,890...27,764,910

G

cyclin dependent kinase 2

decreases expression

Coumestrol results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 2 associated protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK2AP2 mRNA

NCBI chr 1:201,391,056...201,393,137
Ensembl chr 1:201,391,466...201,393,137

G

CDK5 regulatory subunit associated protein 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK5RAP2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDK5RAP2 mRNA
Coumestrol results in increased expression of CDK5RAP2 mRNA

NCBI chr 5:83,792,282...83,961,129
Ensembl chr 5:83,792,284...83,960,782

G

cyclin-dependent kinase-like 5

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CDKL5 mRNA

NCBI chr X:33,757,605...33,988,075
Ensembl chr X:33,821,257...33,986,582

G

cyclin-dependent kinase inhibitor 1A

decreases expression
multiple interactions

Coumestrol results in decreased expression of CDKN1A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1C

decreases expression

Coumestrol results in decreased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

CDKN2A interacting protein

decreases expression

Coumestrol results in decreased expression of CDKN2AIP mRNA

NCBI chr16:44,536,147...44,546,216
Ensembl chr16:44,536,234...44,540,033

G

cyclin-dependent kinase inhibitor 2B

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN2B mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CDKN2B mRNA
Coumestrol results in decreased expression of CDKN2B mRNA

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

cyclin-dependent kinase inhibitor 2C

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDKN2C mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA]
Coumestrol results in increased expression of CDKN2C mRNA

PMID:18310284 PMID:19167446

NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278

G

cyclin-dependent kinase inhibitor 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDKN3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDKN3 mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA]
Coumestrol results in increased expression of CDKN3 mRNA

PMID:18310284 PMID:19167446

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

CDP-diacylglycerol synthase 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CDS1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDS1 mRNA

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

chromatin licensing and DNA replication factor 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDT1 mRNA
Coumestrol results in increased expression of CDT1 mRNA

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

carnitine deficiency-associated gene expressed in ventricle 3

increases expression
multiple interactions

Coumestrol results in increased expression of CDV3 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CDV3 mRNA

NCBI chr 8:103,934,006...103,947,173
Ensembl chr 8:103,933,996...103,947,192

G

chromodomain Y-like

decreases expression

Coumestrol results in decreased expression of CDYL mRNA

NCBI chr17:28,982,009...29,204,345
Ensembl chr17:28,982,037...29,204,313

G

CCAAT/enhancer binding protein delta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

cadherin, EGF LAG seven-pass G-type receptor 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CELSR2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CELSR2 mRNA
Coumestrol results in increased expression of CELSR2 mRNA

NCBI chr 2:196,029,206...196,053,848
Ensembl chr 2:196,029,434...196,053,845

G

centromere protein A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPA mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CENPA mRNA
Coumestrol results in increased expression of CENPA mRNA

NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675

G

centromere protein E

increases expression
multiple interactions

Coumestrol results in increased expression of CENPE mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CENPE mRNA

NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669

G

centromere protein F

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPF mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPF mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA]
Coumestrol results in increased expression of CENPF mRNA

PMID:18310284 PMID:19167446

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

centromere protein H

increases expression
multiple interactions

Coumestrol results in increased expression of CENPH mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPH mRNA

NCBI chr 2:31,896,675...31,910,179
Ensembl chr 2:31,894,667...31,910,154

G

centromere protein I

increases expression
multiple interactions

Coumestrol results in increased expression of CENPI mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPI mRNA

NCBI chr X:97,515,919...97,567,671
Ensembl chr X:97,515,972...97,567,657

G

centromere protein J

increases expression

Coumestrol results in increased expression of CENPJ mRNA

NCBI chr15:30,627,206...30,690,384
Ensembl chr15:30,627,224...30,686,791

G

centromere protein L

increases expression
multiple interactions

Coumestrol results in increased expression of CENPL mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPL mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPL mRNA

NCBI chr13:73,337,235...73,352,115
Ensembl chr13:73,337,257...73,352,114

G

centromere protein M

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CENPM mRNA
Coumestrol results in increased expression of CENPM mRNA

NCBI chr 7:113,748,026...113,759,296
Ensembl chr 7:113,747,516...113,764,258

G

centromere protein N

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPN mRNA
Coumestrol results in increased expression of CENPN mRNA

NCBI chr19:44,971,265...44,994,019
Ensembl chr19:44,968,308...44,994,012

G

centromere protein O

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPO mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPO mRNA
Coumestrol results in increased expression of CENPO mRNA

NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314

G

centromere protein Q

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPQ mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPQ mRNA
Coumestrol results in increased expression of CENPQ mRNA

NCBI chr 9:19,957,122...19,972,807
Ensembl chr 9:19,957,048...19,972,789

G

centromere protein S

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPS mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CENPS mRNA
Coumestrol results in increased expression of CENPS mRNA

NCBI chr 5:159,563,917...159,573,534

G

centromere protein U

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPU mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPU mRNA
Coumestrol results in increased expression of CENPU mRNA

NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823

G

centromere protein W

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPW mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPW mRNA
Coumestrol results in increased expression of CENPW mRNA

NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464

G

centrosomal protein 128

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CEP128 mRNA

NCBI chr 6:109,951,009...110,328,686
Ensembl chr 6:109,951,061...110,328,713

G

centrosomal protein 15

increases expression

Coumestrol results in increased expression of CEP15 mRNA

NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838

G

centrosomal protein 152

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CEP152 mRNA
Coumestrol results in increased expression of CEP152 mRNA

NCBI chr 3:112,803,185...112,878,298
Ensembl chr 3:112,810,425...112,878,458
Ensembl chr 3:112,810,425...112,878,458

G

centrosomal protein 192

increases expression

Coumestrol results in increased expression of CEP192 mRNA

NCBI chr18:61,373,937...61,458,405
Ensembl chr18:61,332,158...61,458,379

G

centrosomal protein 55

increases expression
multiple interactions

Coumestrol results in increased expression of CEP55 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP55 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CEP55 mRNA

NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394

G

centrosomal protein 57

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CEP57 mRNA
Coumestrol results in increased expression of CEP57 mRNA

NCBI chr 8:10,669,588...10,689,257
Ensembl chr 8:10,669,590...10,689,249

G

centrosomal protein 57-like 1

increases expression

Coumestrol results in increased expression of CEP57L1 mRNA

NCBI chr20:45,238,039...45,294,575
Ensembl chr20:45,238,044...45,294,540

G

centrosomal protein 78

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP78 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CEP78 mRNA
Coumestrol results in increased expression of CEP78 mRNA

NCBI chr 1:213,246,183...213,275,275
Ensembl chr 1:213,246,187...213,275,181

G

centrosomal protein 85

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP85 mRNA
Coumestrol results in increased expression of CEP85 mRNA

NCBI chr 5:146,356,571...146,404,155
Ensembl chr 5:146,356,576...146,404,060

G

cilia and flagella associated protein 20

increases expression

Coumestrol results in increased expression of CFAP20 mRNA

NCBI chr19:9,608,867...9,622,558
Ensembl chr19:9,608,859...9,622,558

G

CASP8 and FADD-like apoptosis regulator

decreases expression

Coumestrol results in decreased expression of CFLAR mRNA

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

cingulin

decreases expression

Coumestrol results in decreased expression of CGN mRNA

NCBI chr 2:182,308,389...182,335,747
Ensembl chr 2:182,308,714...182,334,645

G

ChaC glutathione specific gamma-glutamylcyclotransferase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAC2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHAC2 mRNA
Coumestrol results in increased expression of CHAC2 mRNA

NCBI chr14:104,720,754...104,728,305
Ensembl chr14:104,720,758...104,728,301

G

chromatin assembly factor 1 subunit A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAF1A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHAF1A mRNA
Coumestrol results in increased expression of CHAF1A mRNA

NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654

G

chromatin assembly factor 1 subunit B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAF1B mRNA
Coumestrol results in increased expression of CHAF1B mRNA

NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070

G

chromodomain helicase DNA binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CHD2 mRNA

NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502

G

chromodomain helicase DNA binding protein 6

decreases expression

Coumestrol results in decreased expression of CHD6 mRNA

NCBI chr 3:149,596,509...149,757,765
Ensembl chr 3:149,596,509...149,757,755

G

checkpoint kinase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHEK1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHEK1 mRNA
Coumestrol results in increased expression of CHEK1 mRNA

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

checkpoint kinase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHEK2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

chimerin 1

increases expression

Coumestrol results in increased expression of CHN1 mRNA

NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490

G

choline phosphotransferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHPT1 mRNA

NCBI chr 7:22,866,455...22,915,111
Ensembl chr 7:22,863,027...22,915,103

G

cholinergic receptor nicotinic alpha 5 subunit

increases expression

Coumestrol results in increased expression of CHRNA5 mRNA

NCBI chr 8:55,369,794...55,398,526
Ensembl chr 8:55,369,794...55,398,146

G

cellular inhibitor of PP2A

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CIP2A mRNA

NCBI chr11:51,792,143...51,823,016
Ensembl chr11:51,795,024...51,822,938

G

CDGSH iron sulfur domain 1

increases expression

Coumestrol results in increased expression of CISD1 mRNA

NCBI chr20:17,255,302...17,268,688
Ensembl chr20:17,255,151...17,284,924

G

citron rho-interacting serine/threonine kinase

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CIT mRNA

NCBI chr12:40,603,073...40,764,846
Ensembl chr12:40,605,563...40,763,860

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CITED2 mRNA

NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897

G

cytoskeleton associated protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CKAP2 mRNA

NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913

G

cytoskeleton associated protein 2-like

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CKAP2L mRNA
Coumestrol results in increased expression of CKAP2L mRNA

NCBI chr 3:116,497,186...116,524,302
Ensembl chr 3:116,498,022...116,524,366

G

cytoskeleton-associated protein 4

decreases expression

Coumestrol results in decreased expression of CKAP4 mRNA

NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914

G

cytoskeleton associated protein 5

increases expression
multiple interactions

Coumestrol results in increased expression of CKAP5 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKAP5 mRNA

NCBI chr 3:77,491,195...77,593,300
Ensembl chr 3:77,491,276...77,593,264

G

chemokine-like factor

increases expression
multiple interactions

Coumestrol results in increased expression of CKLF mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKLF mRNA

NCBI chr19:698,097...706,570
Ensembl chr19:698,033...706,570

G

CDC28 protein kinase regulatory subunit 1B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKS1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CKS1B mRNA
Coumestrol results in increased expression of CKS1B mRNA

NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636

G

CDC28 protein kinase regulatory subunit 2

increases expression
multiple interactions

Coumestrol results in increased expression of CKS2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKS2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CKS2 mRNA

NCBI chr17:13,570,611...13,575,770

G

chloride channel CLIC-like 1

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA]

NCBI chr 2:196,296,350...196,326,914
Ensembl chr 2:196,296,393...196,326,913

G

claudin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLDN1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLDN4 mRNA

NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436

G

CAP-GLY domain containing linker protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLIP1 mRNA

NCBI chr12:32,910,932...33,017,891
Ensembl chr12:32,910,977...33,017,884

G

CLN6, transmembrane ER protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CLN6 mRNA

NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360

G

CLN8, transmembrane ER and ERGIC protein

decreases expression

Coumestrol results in decreased expression of CLN8 mRNA

NCBI chr16:74,749,662...74,759,553
Ensembl chr16:74,749,662...74,759,774

G

collectrin, amino acid transport regulator

decreases expression

Coumestrol results in decreased expression of CLTRN mRNA

NCBI chr X:30,361,967...30,395,264
Ensembl chr X:30,361,967...30,395,349

G

clusterin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

C-x(9)-C motif containing 2

increases expression
multiple interactions

Coumestrol results in increased expression of CMC2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CMC2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CMC2 mRNA

NCBI chr19:44,943,283...44,971,930
Ensembl chr19:44,943,285...44,971,983

G

cms1 ribosomal small subunit homolog

increases expression
multiple interactions

Coumestrol results in increased expression of CMSS1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CMSS1 mRNA

NCBI chr11:42,934,390...43,232,624
Ensembl chr11:42,934,440...43,232,624

G

CKLF-like MARVEL transmembrane domain containing 8

decreases expression

Coumestrol results in decreased expression of CMTM8 mRNA

NCBI chr 8:114,481,730...114,547,107
Ensembl chr 8:114,481,982...114,547,083

G

cordon-bleu WH2 repeat protein

decreases expression

Coumestrol results in decreased expression of COBL mRNA

NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800

G

cochlin

increases expression

Coumestrol results in increased expression of COCH mRNA

NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109

G

component of oligomeric golgi complex 4

increases expression

Coumestrol results in increased expression of COG4 mRNA

NCBI chr19:38,820,478...38,854,803
Ensembl chr19:38,820,501...38,854,796

G

component of oligomeric golgi complex 5

decreases expression

Coumestrol results in decreased expression of COG5 mRNA

NCBI chr 6:48,242,470...48,545,185
Ensembl chr 6:48,242,482...48,529,009

G

component of oligomeric golgi complex 6

decreases expression

Coumestrol results in decreased expression of COG6 mRNA

NCBI chr 2:137,062,127...137,099,176
Ensembl chr 2:137,061,346...137,099,190

G

COMM domain containing 4

increases expression

Coumestrol results in increased expression of COMMD4 mRNA

NCBI chr 8:57,566,236...57,569,701
Ensembl chr 8:57,566,236...57,569,760

G

catechol-O-methyltransferase

decreases expression
multiple interactions

Coumestrol results in decreased expression of COMT mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of COMT mRNA

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

COP9 signalosome subunit 2

decreases expression

Coumestrol results in decreased expression of COPS2 mRNA

NCBI chr 3:113,084,174...113,110,090
Ensembl chr 3:113,084,176...113,109,947

G

coenzyme Q2, polyprenyltransferase

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of COQ2 mRNA

NCBI chr14:8,941,429...8,961,418
Ensembl chr14:8,941,461...8,960,891

G

coenzyme Q7, hydroxylase

increases expression

Coumestrol results in increased expression of COQ7 mRNA

NCBI chr 1:172,836,359...172,851,173
Ensembl chr 1:172,835,188...172,851,158

G

coronin 1B

decreases expression
multiple interactions

Coumestrol results in decreased expression of CORO1B mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CORO1B mRNA

NCBI chr 1:201,442,977...201,448,416
Ensembl chr 1:201,443,014...201,448,416

G

coronin 1C

increases expression

Coumestrol results in increased expression of CORO1C mRNA

NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179

G

coronin 2A

decreases expression
multiple interactions

Coumestrol results in decreased expression of CORO2A mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CORO2A mRNA

NCBI chr 5:60,825,630...60,881,917
Ensembl chr 5:60,828,247...60,859,035

G

carboxypeptidase E

decreases expression

Coumestrol results in decreased expression of CPE mRNA

NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233

G

cytoplasmic polyadenylation element binding protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CPEB2 mRNA

NCBI chr14:67,787,503...67,839,973
Ensembl chr14:67,787,507...67,840,743

G

cleavage and polyadenylation specific factor 3

increases expression

Coumestrol results in increased expression of CPSF3 mRNA

NCBI chr 6:40,836,121...40,864,129
Ensembl chr 6:40,836,097...40,864,128

G

capping protein inhibiting regulator of actin dynamics

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CRACD mRNA
Coumestrol results in decreased expression of CRACD mRNA

NCBI chr14:31,284,066...31,520,103
Ensembl chr14:31,284,184...31,522,431

G

cAMP responsive element binding protein 3-like 4

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CREB3L4 mRNA

NCBI chr 2:175,690,340...175,695,846
Ensembl chr 2:175,690,335...175,695,932

G

cysteine-rich protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CRIP2 mRNA

NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065

G

cryptochrome circadian regulator 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CRY1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CRY1 mRNA

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

chromosome segregation 1 like

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CSE1L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CSE1L mRNA
Coumestrol results in increased expression of CSE1L mRNA

NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865

G

casein kinase 1, alpha 1

decreases expression

Coumestrol results in decreased expression of CSNK1A1 mRNA

NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271

G

casein kinase 1, gamma 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CSNK1G1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CSNK1G1 mRNA

NCBI chr 8:66,439,760...66,577,247
Ensembl chr 8:66,439,864...66,572,826

G

casein kinase 1, gamma 3

decreases expression

Coumestrol results in decreased expression of CSNK1G3 mRNA

NCBI chr18:47,299,547...47,386,538
Ensembl chr18:47,299,579...47,386,535

G

casein kinase 2 alpha 2

decreases expression

Coumestrol results in decreased expression of CSNK2A2 mRNA

NCBI chr19:9,556,443...9,596,080
Ensembl chr19:9,556,260...9,596,080

G

chondroitin sulfate proteoglycan 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CSPG5 mRNA

NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758

G

cysteine and serine rich nuclear protein 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AXUD1 mRNA
Coumestrol results in decreased expression of AXUD1 mRNA

NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183

G

cysteine and serine rich nuclear protein 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of CSRNP2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CSRNP2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CSRNP2 mRNA

NCBI chr 7:131,594,232...131,610,075
Ensembl chr 7:131,594,232...131,610,075

G

cystatin A

decreases expression
multiple interactions

Coumestrol results in decreased expression of CSTA mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CSTA mRNA

NCBI chr11:64,620,483...64,631,488
Ensembl chr11:64,620,483...64,631,488

G

cleavage stimulation factor subunit 1

increases expression

Coumestrol results in increased expression of CSTF1 mRNA

NCBI chr 3:161,144,522...161,156,294
Ensembl chr 3:161,144,548...161,156,300

G

cleavage stimulation factor subunit 2

increases expression

Coumestrol results in increased expression of CSTF2 mRNA

NCBI chr X:97,253,559...97,279,476
Ensembl chr X:97,253,586...97,279,476

G

C-terminal binding protein 1

decreases expression

Coumestrol results in decreased expression of CTBP1 mRNA

NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821

G

CTD small phosphatase like 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTDSPL2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CTDSPL2 mRNA
Coumestrol results in increased expression of CTDSPL2 mRNA

NCBI chr 3:108,915,263...108,970,620
Ensembl chr 3:108,915,280...108,967,227

G

catenin alpha-like 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTNNAL1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CTNNAL1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA]
Coumestrol results in increased expression of CTNNAL1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431

G

catenin delta 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CTNND1 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CTNND1 mRNA

NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516

G

catenin delta 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of CTNND2 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CTNND2 mRNA

NCBI chr 2:81,168,525...82,016,495
Ensembl chr 2:81,167,117...82,015,764

G

CTP synthase 1

increases expression
multiple interactions

Coumestrol results in increased expression of CTPS1 mRNA
[Coumestrol co-treated with Resveratrol] results in increased expression of CTPS1 mRNA

NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180

G

CTR9 homolog, Paf1/RNA polymerase II complex component

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTR9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CTR9 mRNA

NCBI chr 1:165,137,277...165,167,303
Ensembl chr 1:165,137,215...165,167,303

G

cathepsin B

decreases expression

Coumestrol results in decreased expression of CTSB mRNA

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin C

increases expression

Coumestrol results in increased expression of CTSC mRNA

NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387

G

cathepsin H

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of CTSH mRNA
Coumestrol results in decreased expression of CTSH mRNA

NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824

G

cortactin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CTTN mRNA

NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164

G

CTTNBP2 N-terminal like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CTTNBP2NL mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of CTTNBP2NL mRNA

NCBI chr 2:192,507,963...192,554,548
Ensembl chr 2:192,507,963...192,541,101

G

C-X-C motif chemokine ligand 12

multiple interactions
increases expression

[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CXCL12 mRNA; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CXCL12 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA]

PMID:18310284 PMID:19167446 PMID:23384675 PMID:28396216

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

CXXC finger protein 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CXXC5 mRNA

NCBI chr18:27,427,591...27,458,579
Ensembl chr18:27,427,230...27,458,673

G

cytochrome b5 type B

increases expression

Coumestrol results in increased expression of CYB5B mRNA

NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249

G

cytochrome b5 reductase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CYB5R1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CYB5R1 mRNA

NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458

G

cytoplasmic FMR1 interacting protein 2

decreases expression

Coumestrol results in decreased expression of CYFIP2 mRNA

NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
multiple interactions

Coumestrol results in increased expression of CYP1B1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CYP1B1 mRNA

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CYP2R1 mRNA

NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759

G

cytochrome P450, family 51

increases expression

Coumestrol results in increased expression of CYP51A1 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

cell cycle regulator of NHEJ

increases expression

Coumestrol results in increased expression of CYREN mRNA

NCBI chr 4:63,547,311...63,553,394
Ensembl chr 4:63,547,335...63,551,602

G

CYFIP related Rac1 interactor B

decreases expression
multiple interactions

Coumestrol results in decreased expression of CYRIB mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CYRIB mRNA

NCBI chr 7:95,633,876...95,760,588
Ensembl chr 7:95,633,876...95,697,686

G

cytohesin 2

decreases expression

Coumestrol results in decreased expression of CYTH2 mRNA

NCBI chr 1:96,283,182...96,291,094
Ensembl chr 1:96,284,252...96,291,092

G

dishevelled associated activator of morphogenesis 1

decreases expression

Coumestrol results in decreased expression of DAAM1 mRNA

NCBI chr 6:90,389,544...90,550,114
Ensembl chr 6:90,389,688...90,550,114

G

differentiation antagonizing non-protein coding RNA

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DANCR mRNA

NCBI chr14:34,126,956...34,127,936

G

aspartyl-tRNA synthetase 2 (mitochondrial)

increases expression
multiple interactions

Coumestrol results in increased expression of DARS2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DARS2 mRNA

NCBI chr13:73,308,726...73,336,558
Ensembl chr13:73,308,726...73,336,934

G

DBF4-CDC7 kinase regulatory subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DBF4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DBF4 mRNA
Coumestrol results in increased expression of DBF4 mRNA

NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066

G

drebrin 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DBN1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DBN1 mRNA
Coumestrol results in decreased expression of DBN1 mRNA

NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984

G

DDB1 and CUL4 associated factor 15

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCAF15 mRNA

NCBI chr19:24,053,925...24,061,277
Ensembl chr19:24,053,925...24,061,277

G

DDB1 and CUL4 associated factor 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCAF4 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DCAF4 mRNA

NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982

G

DDB1 and CUL4 associated factor 5

decreases expression
multiple interactions

Coumestrol results in decreased expression of DCAF5 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCAF5 mRNA

NCBI chr 6:99,171,506...99,260,183
Ensembl chr 6:99,171,506...99,260,110

G

deoxycytidine kinase

increases expression
multiple interactions

Coumestrol results in increased expression of DCK mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of DCK mRNA

NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247

G

doublecortin-like kinase 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of DCLK1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCLK1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DCLK1 mRNA

NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956

G

DNA cross-link repair 1A

increases expression
multiple interactions

Coumestrol results in increased expression of DCLRE1A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCLRE1A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DCLRE1A mRNA

NCBI chr 1:255,569,911...255,589,815
Ensembl chr 1:255,569,919...255,589,678

G

DNA cross-link repair 1B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCLRE1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DCLRE1B mRNA
Coumestrol results in increased expression of DCLRE1B mRNA

NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423

G

decapping enzyme, scavenger

increases expression

Coumestrol results in increased expression of DCPS mRNA

NCBI chr 8:33,468,669...33,524,407
Ensembl chr 8:33,415,671...33,524,389

G

dCTP pyrophosphatase 1

increases expression

Coumestrol results in increased expression of DCTPP1 mRNA

NCBI chr 1:181,877,440...181,880,833
Ensembl chr 1:181,877,437...181,880,839

G

DDAH family member 2, ADMA-independent

decreases expression
multiple interactions

Coumestrol results in decreased expression of DDAH2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DDAH2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DDAH2 mRNA

NCBI chr20:3,761,460...3,764,718
Ensembl chr20:3,761,465...3,764,511

G

damage specific DNA binding protein 2

increases expression
multiple interactions

Coumestrol results in increased expression of DDB2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDB2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DDB2 mRNA

NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631

G

DNA damage-induced apoptosis suppressor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDIAS mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DDIAS mRNA
Coumestrol results in increased expression of DDIAS mRNA

NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462

G

DNA-damage-inducible transcript 4

decreases expression
multiple interactions

Coumestrol results in decreased expression of DDIT4 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

DEAD/H-box helicase 11

increases expression

Coumestrol results in increased expression of DDX11 mRNA

NCBI chr 9:105,833,234...105,862,844
Ensembl chr 9:105,833,504...105,862,550

G

DExD-box helicase 39A

increases expression

Coumestrol results in increased expression of DDX39A mRNA

NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954

G

DExD-box helicase 39B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDX39B mRNA

NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996

G

DEAD-box helicase 56

increases expression

Coumestrol results in increased expression of DDX56 mRNA

NCBI chr14:81,112,008...81,122,331
Ensembl chr14:81,112,012...81,122,333

G

DEK proto-oncogene

increases expression
multiple interactions

Coumestrol results in increased expression of DEK mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of DEK mRNA

NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808

G

DENN domain containing 11

decreases expression
multiple interactions

Coumestrol results in decreased expression of DENND11 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DENND11 mRNA

NCBI chr 4:69,197,161...69,266,013
Ensembl chr 4:69,198,068...69,228,821

G

DENN domain containing 1A

increases expression

Coumestrol results in increased expression of DENND1A mRNA

NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062

G

DENN domain containing 1B

decreases expression

Coumestrol results in decreased expression of DENND1B mRNA

NCBI chr13:50,545,324...50,772,922
Ensembl chr13:50,545,836...50,770,601

G

DENN domain containing 1C

decreases expression

Coumestrol results in decreased expression of DENND1C mRNA

NCBI chr 9:1,904,040...1,916,329
Ensembl chr 9:1,904,045...1,916,187

G

density regulated reinitiation and release factor

increases expression

Coumestrol results in increased expression of DENR mRNA

NCBI chr12:32,662,512...32,685,283
Ensembl chr12:32,662,516...32,683,843

G

DEP domain containing 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DEPDC1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DEPDC1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA]
Coumestrol results in increased expression of DEPDC1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 2:248,684,508...248,717,951
Ensembl chr 2:248,684,523...248,717,951

G

DEP domain containing 1B

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA]

NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779

G

DEP domain containing MTOR-interacting protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DEPTOR mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of DEPTOR mRNA
Coumestrol results in increased expression of DEPTOR mRNA

NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773

G

deoxyribose-phosphate aldolase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DERA mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DERA mRNA
Coumestrol results in increased expression of DERA mRNA

NCBI chr 4:170,663,689...170,742,469
Ensembl chr 4:170,663,665...170,758,865

G

desumoylating isopeptidase 2

increases expression

Coumestrol results in increased expression of DESI2 mRNA

NCBI chr13:89,961,767...90,011,255
Ensembl chr13:89,961,934...90,016,416

G

7-dehydrocholesterol reductase

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of DHCR7 mRNA
Coumestrol results in increased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

dihydrofolate reductase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHFR mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of DHFR mRNA
Coumestrol results in increased expression of DHFR mRNA

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

dehydrogenase/reductase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHRS2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DHRS2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA]
Coumestrol results in increased expression of DHRS2 mRNA

PMID:18310284 PMID:19167446

NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644

G

dehydrogenase/reductase 7

decreases expression

Coumestrol results in decreased expression of DHRS7 mRNA

NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892

G

dehydrogenase E1 and transketolase domain containing 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHTKD1 mRNA
Coumestrol results in increased expression of DHTKD1 mRNA

NCBI chr17:72,355,201...72,406,725
Ensembl chr17:72,355,201...72,406,723

G

diaphanous-related formin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DIAPH3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DIAPH3 mRNA

NCBI chr15:62,543,375...63,013,060
Ensembl chr15:62,543,375...63,012,975

G

dicer 1 ribonuclease III

decreases expression

Coumestrol results in decreased expression of DICER1 mRNA

NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965

G

disco-interacting protein 2 homolog C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DIP2C mRNA

NCBI chr17:60,647,346...61,032,467
Ensembl chr17:60,649,065...61,032,305

G

DIX domain containing 1

decreases expression

Coumestrol results in decreased expression of DIXDC1 mRNA

NCBI chr 8:51,007,835...51,081,191
Ensembl chr 8:51,007,838...51,081,090

G

dyskerin pseudouridine synthase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DKC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DKC1 mRNA
Coumestrol results in increased expression of DKC1 mRNA

G

dihydrolipoamide S-acetyltransferase

increases expression

Coumestrol results in increased expression of DLAT mRNA

NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479

G

DLG associated protein 5

increases expression
multiple interactions

Coumestrol results in increased expression of DLGAP5 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DLGAP5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DLGAP5 mRNA

NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518

G

distal-less homeobox 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DLX2 mRNA

NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597

G

distal membrane arm assembly component 2 like

decreases expression

Coumestrol results in decreased expression of DMAC2L mRNA

NCBI chr 6:88,205,580...88,223,934
Ensembl chr 6:88,205,700...88,223,933

G

Dmx-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DMXL1 mRNA

NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456

G

DnaJ heat shock protein family (Hsp40) member A2

decreases expression
multiple interactions

Coumestrol results in decreased expression of DNAJA2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNAJA2 mRNA

NCBI chr19:21,497,792...21,516,904
Ensembl chr19:21,497,729...21,516,901

G

DnaJ heat shock protein family (Hsp40) member B9

decreases expression
multiple interactions

Coumestrol results in decreased expression of DNAJB9 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C1

decreases expression

Coumestrol results in decreased expression of DNAJC1 mRNA

NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988

G

DnaJ heat shock protein family (Hsp40) member C16

decreases expression

Coumestrol results in decreased expression of DNAJC16 mRNA

NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136

G

DnaJ heat shock protein family (Hsp40) member C9

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNAJC9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DNAJC9 mRNA
Coumestrol results in increased expression of DNAJC9 mRNA

NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118

G

deoxyribonuclease 2, lysosomal

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNASE2 mRNA

NCBI chr19:23,244,656...23,247,376
Ensembl chr19:23,244,664...23,247,376

G

dynamin 1-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNM1L mRNA

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

DNA methyltransferase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNMT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DNMT1 mRNA
Coumestrol results in increased expression of DNMT1 mRNA

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

dedicator of cytokinesis 8

decreases expression

Coumestrol results in decreased expression of DOCK8 mRNA

NCBI chr 1:222,649,309...222,842,474
Ensembl chr 1:222,649,309...222,842,474

G

DNA replication fork stabilization factor DONSON

increases expression
multiple interactions

Coumestrol results in increased expression of DONSON mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DONSON mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DONSON mRNA

NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889

G

DOP1 leucine zipper like protein B

decreases expression

Coumestrol results in decreased expression of DOP1B mRNA

NCBI chr11:33,024,376...33,125,931
Ensembl chr11:33,024,411...33,125,931

G

dolichyl-phosphate N-acetylglucosaminephosphotransferase 1

increases expression

Coumestrol results in increased expression of DPAGT1 mRNA

NCBI chr 8:44,664,055...44,671,102
Ensembl chr 8:44,664,071...44,671,087

G

dolichyl-phosphate mannosyltransferase subunit 2, regulatory

increases expression

Coumestrol results in increased expression of DPM2 mRNA

NCBI chr 3:15,855,952...15,858,867
Ensembl chr 3:15,856,182...15,869,165
Ensembl chr 3:15,856,182...15,869,165

G

dpy-19 like C-mannosyltransferase 1

increases expression

Coumestrol results in increased expression of DPY19L1 mRNA

NCBI chr 8:22,933,163...23,021,461
Ensembl chr 8:22,933,163...23,021,751

G

desmocollin 2

decreases expression

Coumestrol results in decreased expression of DSC2 mRNA

NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392

G

DNA replication and sister chromatid cohesion 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DSCC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DSCC1 mRNA
Coumestrol results in increased expression of DSCC1 mRNA

NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212

G

DSN1 component of MIS12 kinetochore complex

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DSN1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DSN1 mRNA
Coumestrol results in increased expression of DSN1 mRNA

NCBI chr 3:145,652,741...145,668,025
Ensembl chr 3:145,652,737...145,665,856

G

dystrobrevin, alpha

decreases expression
multiple interactions

Coumestrol results in decreased expression of DTNA mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DTNA mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DTNA mRNA

NCBI chr18:14,687,193...14,944,232
Ensembl chr18:14,587,852...14,944,261

G

dual specificity phosphatase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DUSP1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 10

decreases expression
multiple interactions

Coumestrol results in decreased expression of DUSP10 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of DUSP10 mRNA

NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716

G

dual specificity phosphatase 22

decreases expression

Coumestrol results in decreased expression of DUSP22 mRNA

NCBI chr17:33,780,980...33,831,241
Ensembl chr17:33,780,981...33,831,321

G

deoxyuridine triphosphatase

increases expression
multiple interactions

Coumestrol results in increased expression of DUT mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DUT mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of DUT mRNA

NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771

G

dynein cytoplasmic 1 light intermediate chain 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of DYNC1LI1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DYNC1LI1 mRNA

NCBI chr 8:114,376,649...114,410,297
Ensembl chr 8:114,376,662...114,410,934

G

dynein 2 intermediate chain 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DYNC2I2 mRNA

NCBI chr 3:13,306,039...13,322,121
Ensembl chr 3:13,306,039...13,322,121

G

dynein light chain Tctex-type 3

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of DYNLT3 mRNA

NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139

G

E2F transcription factor 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

E2F transcription factor 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of E2F2 mRNA
Coumestrol results in increased expression of E2F2 mRNA

NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217

G

E2F transcription factor 5

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of E2F5 mRNA
Coumestrol results in decreased expression of E2F5 mRNA

NCBI chr 2:86,997,331...87,012,908
Ensembl chr 2:86,997,332...87,012,990

G

E2F transcription factor 7

increases expression
multiple interactions

Coumestrol results in increased expression of E2F7 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F7 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of E2F7 mRNA

NCBI chr 7:46,150,533...46,192,739
Ensembl chr 7:46,151,293...46,192,734

G

E2F transcription factor 8

increases expression
multiple interactions

Coumestrol results in increased expression of E2F8 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F8 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of E2F8 mRNA

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

EBP, cholestenol delta-isomerase

increases expression
multiple interactions

Coumestrol results in increased expression of EBP mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EBP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EBP mRNA

NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826

G

epithelial cell transforming 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ECT2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ECT2 mRNA
Coumestrol results in increased expression of ECT2 mRNA

NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911

G

ER degradation enhancing alpha-mannosidase like protein 3

decreases expression

Coumestrol results in decreased expression of EDEM3 mRNA

NCBI chr13:63,858,282...63,920,538
Ensembl chr13:63,858,716...63,920,523

G

EGF like repeats and discoidin domains 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EDIL3 mRNA

NCBI chr 2:19,890,396...20,405,028
Ensembl chr 2:19,890,373...20,405,008

G

endothelin 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of EDN1 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of EDN1 mRNA

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

embryonic ectoderm development

increases expression
multiple interactions

Coumestrol results in increased expression of EED mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EED mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EED mRNA

NCBI chr 1:143,867,875...143,895,008
Ensembl chr 1:143,867,875...143,894,974

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EEF1A1 mRNA

NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839

G

EGF containing fibulin extracellular matrix protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFEMP1 mRNA

NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018

G

EF-hand domain family, member D1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFHD1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EFHD1 mRNA
Coumestrol results in decreased expression of EFHD1 mRNA

NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917

G

ephrin A1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFNA1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EFNA1 mRNA
Coumestrol results in decreased expression of EFNA1 mRNA

NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866

G

ephrin B2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFNB2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EFNB2 mRNA
Coumestrol results in decreased expression of EFNB2 mRNA

NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391

G

ephrin B3

decreases expression

Coumestrol results in decreased expression of EFNB3 mRNA

NCBI chr10:54,274,506...54,281,951
Ensembl chr10:54,274,506...54,280,471

G

elongation factor Tu GTP binding domain containing 2

increases expression

Coumestrol results in increased expression of EFTUD2 mRNA

NCBI chr10:87,804,893...87,852,181
Ensembl chr10:87,804,892...87,846,079

G

early growth response 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EGR3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EGR3 mRNA

NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627

G

euchromatic histone lysine methyltransferase 1

decreases expression

Coumestrol results in decreased expression of EHMT1 mRNA

NCBI chr 3:7,580,680...7,729,046
Ensembl chr 3:7,580,683...7,729,007

G

eukaryotic translation initiation factor 2 alpha kinase 3

decreases expression

Coumestrol results in decreased expression of EIF2AK3 mRNA

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases expression

Coumestrol results in increased expression of EIF2S1 mRNA

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

eukaryotic translation initiation factor 4E binding protein 2

increases expression

Coumestrol results in increased expression of EIF4EBP2 mRNA

NCBI chr20:29,379,444...29,400,110
Ensembl chr20:29,382,668...29,399,946

G

eukaryotic translation initiation factor 4 gamma, 3

decreases expression

Coumestrol results in decreased expression of EIF4G3 mRNA

NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363

G

endosome-lysosome associated apoptosis and autophagy regulator 1

multiple interactions

[Coumestrol co-treated with Resveratrol] results in decreased expression of ELAPOR1 mRNA

NCBI chr 2:196,089,199...196,169,055
Ensembl chr 2:196,091,646...196,168,716

G

E74 like ETS transcription factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ELF5 mRNA

NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973

G

ETS transcription factor ELK1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELK1 mRNA

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

ETS transcription factor ELK3

decreases expression

Coumestrol results in decreased expression of ELK3 mRNA

NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084

G

engulfment and cell motility 2

decreases expression

Coumestrol results in decreased expression of ELMO2 mRNA

NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:154,023,661...154,061,185

G

ELOVL fatty acid elongase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ELOVL2 mRNA
Coumestrol results in increased expression of ELOVL2 mRNA

NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,544,568...23,584,848

G

ELOVL fatty acid elongase 5

increases expression
multiple interactions

Coumestrol results in increased expression of ELOVL5 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of ELOVL5 mRNA

NCBI chr 8:78,790,846...78,857,307
Ensembl chr 8:78,790,846...78,857,284

G

ELOVL fatty acid elongase 6

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ELOVL6 mRNA
Coumestrol results in increased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

ELOVL fatty acid elongase 7

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL7 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ELOVL7 mRNA
Coumestrol results in increased expression of ELOVL7 mRNA

NCBI chr 2:39,789,229...39,858,579
Ensembl chr 2:39,789,250...39,856,845

G

elongator acetyltransferase complex subunit 5

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of ELP5 mRNA
Coumestrol results in increased expression of ELP5 mRNA

NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923

G

elongator acetyltransferase complex subunit 6

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELP6 mRNA
Coumestrol results in increased expression of ELP6 mRNA

NCBI chr 8:110,280,059...110,295,070
Ensembl chr 8:110,279,979...110,295,067

G

ER membrane protein complex subunit 9

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EMC9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EMC9 mRNA
Coumestrol results in increased expression of EMC9 mRNA

NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098

G

emerin

increases expression

Coumestrol results in increased expression of EMD mRNA

NCBI chr X:152,038,990...152,042,190
Ensembl chr X:152,038,998...152,045,807

G

essential meiotic structure-specific endonuclease 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EME1 mRNA

NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435

G

ectodermal-neural cortex 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of ENC1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ENC1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ENC1 mRNA

NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713

G

endonuclease domain containing 1

increases expression
multiple interactions

Coumestrol results in increased expression of ENDOD1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ENDOD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ENDOD1 mRNA

NCBI chr 8:11,209,113...11,238,507
Ensembl chr 8:11,211,110...11,238,892

G

enolase superfamily member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ENOSF1 mRNA

NCBI chr 9:113,275,267...113,314,842

G

ectonucleoside triphosphate diphosphohydrolase 2

decreases expression

Coumestrol results in decreased expression of ENTPD2 mRNA

NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866

G

ectonucleoside triphosphate diphosphohydrolase 4

decreases expression

Coumestrol results in decreased expression of ENTPD4 mRNA

NCBI chr15:44,630,878...44,658,654
Ensembl chr15:44,630,873...44,658,706

G

endosomal transmembrane epsin interactor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ENTREP1 mRNA

NCBI chr 1:221,592,500...221,646,603
Ensembl chr 1:221,592,503...221,646,758

G

erythrocyte membrane protein band 4.1-like 2

decreases expression

Coumestrol results in decreased expression of EPB41L2 mRNA

NCBI chr 1:19,863,010...20,037,795
Ensembl chr 1:19,863,009...20,037,721

G

erythrocyte membrane protein band 4.1 like 5

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EPB41L5 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EPB41L5 mRNA
Coumestrol results in decreased expression of EPB41L5 mRNA

NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360

G

Eph receptor A4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EPHA4 mRNA

NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139

G

epidermal growth factor receptor pathway substrate 15-like 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EPS15L1 mRNA
Coumestrol results in increased expression of EPS15L1 mRNA

NCBI chr16:17,426,345...17,501,677
Ensembl chr16:17,426,421...17,501,677

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 3

decreases expression

Coumestrol results in decreased expression of ERBB3 mRNA

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB4 mRNA

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

ERCC excision repair 6 like, spindle assembly checkpoint helicase

increases expression
multiple interactions

Coumestrol results in increased expression of ERCC6L mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ERCC6L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ERCC6L mRNA

NCBI chr X:67,245,414...67,261,222
Ensembl chr X:67,245,414...67,280,756

G

ERI1 exoribonuclease family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ERI2 mRNA

NCBI chr 1:174,140,831...174,168,757
Ensembl chr 1:174,141,993...174,168,665

G

ERBB receptor feedback inhibitor 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of ERRFI1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ERRFI1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ERRFI1 mRNA

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

establishment of sister chromatid cohesion N-acetyltransferase 2

increases expression

Coumestrol results in increased expression of ESCO2 mRNA

NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306

G

extra spindle pole bodies like 1, separase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ESPL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ESPL1 mRNA
Coumestrol results in increased expression of ESPL1 mRNA

NCBI chr 7:133,424,027...133,450,984
Ensembl chr 7:133,424,130...133,450,984

G

estrogen receptor 1

multiple interactions
decreases expression
affects response to substance
increases activity
affects binding

2,2-bis(4-glycidyloxyphenyl)propane analog inhibits the reaction [Coumestrol binds to ESR1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Coumestrol binds to ESR1 protein]; 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; [Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein; [Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA; Benzo(a)pyrene inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; bisphenol F diglycidyl ether analog inhibits the reaction [Coumestrol binds to ESR1 protein]; bisphenol F diglycidyl ether inhibits the reaction [Coumestrol binds to ESR1 protein]; CCND1 protein promotes the reaction [Coumestrol results in increased activity of ESR1 protein]; Coumestrol binds to and results in increased activity of ESR1 protein; Coumestrol inhibits the reaction [16 alpha-iodoestradiol binds to ESR1 protein]; Coumestrol inhibits the reaction [Estradiol binds to ESR1 protein]; Coumestrol promotes the reaction [NCOA2 protein binds to ESR1 protein]; Diethylstilbestrol inhibits the reaction [Coumestrol binds to ESR1 protein]; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CCN5 mRNA]; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CXCL12 mRNA]; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of PGR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA]; Estradiol inhibits the reaction [Coumestrol binds to ESR1 protein]; Fulvestrant inhibits the reaction [[Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein]; Fulvestrant inhibits the reaction [Coumestrol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [Coumestrol results in increased activity of ESR1 protein]; Tamoxifen promotes the reaction [Coumestrol results in increased activity of ESR1 protein mutant form]; tetrabromobisphenol A inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; tetrachlorodian inhibits the reaction [Coumestrol binds to ESR1 protein modified form]
Coumestrol results in decreased expression of ESR1 protein
[Fulvestrant co-treated with Coumestrol] results in increased expression of ESR1 mRNA; Fulvestrant inhibits the reaction [Coumestrol results in decreased expression of ESR1 protein]
ESR1 protein affects the susceptibility to Coumestrol
Coumestrol binds to ESR1 protein; Coumestrol binds to ESR1 protein modified form

PMID:9048584 PMID:9751507 PMID:10397250 PMID:11162928 PMID:11518614 More...

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions
increases expression
affects binding
affects response to substance
increases activity

Coumestrol binds to and results in increased activity of ESR2 protein; Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA]
Coumestrol results in increased expression of ESR2 mRNA
Coumestrol binds to Esr2 protein
Coumestrol results in increased expression of ESR2 protein; Coumestrol results in increased expression of ESR2 protein alternative form
ESR2 protein affects the susceptibility to Coumestrol
ESR2 protein affects the reaction [Coumestrol results in increased expression of SOD2 protein]
Coumestrol binds to ESR2 protein
[Fulvestrant co-treated with Coumestrol] results in increased expression of ESR2 mRNA; Coumestrol inhibits the reaction [16 alpha-iodoestradiol binds to ESR2 protein]; Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein alternative form]
Coumestrol results in increased activity of ESR2 protein

CTD
RGD

PMID:9048584 PMID:9492041 PMID:9751507 PMID:11518614 PMID:12224631 More...

RGD:8694130, RGD:8694130

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

extended synaptotagmin 2

decreases expression

Coumestrol results in decreased expression of ESYT2 mRNA

NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590

G

ethanolamine kinase 1

decreases expression

Coumestrol results in decreased expression of ETNK1 mRNA

NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770

G

ecotropic viral integration site 5

decreases expression

Coumestrol results in decreased expression of EVI5 mRNA

NCBI chr14:1,875,601...2,021,678
Ensembl chr14:1,875,647...2,021,678

G

exonuclease 1

increases expression
multiple interactions

Coumestrol results in increased expression of EXO1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EXO1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EXO1 mRNA

NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654

G

exocyst complex component 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EXOC2 mRNA

NCBI chr17:33,506,289...33,698,246
Ensembl chr17:33,506,338...33,693,289

G

exosome component 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of EXOSC2 mRNA

NCBI chr 3:14,962,930...14,973,645
Ensembl chr 3:14,962,917...14,973,575

G

exosome component 3

increases expression

Coumestrol results in increased expression of EXOSC3 mRNA

NCBI chr 5:59,573,849...59,579,065
Ensembl chr 5:59,573,886...59,579,060

G

exosome component 8

increases expression

Coumestrol results in increased expression of EXOSC8 mRNA

NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928

G

exosome component 9

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA]

NCBI chr 2:119,416,028...119,426,981
Ensembl chr 2:119,388,715...119,427,051

G

exostosin glycosyltransferase 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EXT1 mRNA
Coumestrol results in decreased expression of EXT1 mRNA

NCBI chr 7:84,375,769...84,654,625
Ensembl chr 7:84,375,784...84,655,357

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

increases expression
multiple interactions

Coumestrol results in increased expression of EZH2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EZH2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EZH2 mRNA

NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362

G

ezrin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EZR mRNA

NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505

G

coagulation factor II (thrombin) receptor

decreases expression

Coumestrol results in decreased expression of F2R mRNA

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870

G

F2R like trypsin receptor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of F2RL1 mRNA
Coumestrol results in decreased expression of F2RL1 mRNA

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

fatty acid binding protein 5

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA]

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

fatty acid desaturase 1

increases expression
multiple interactions

Coumestrol results in increased expression of FADS1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of FADS1 mRNA

NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734

G

fumarylacetoacetate hydrolase

increases expression

Coumestrol results in increased expression of FAH mRNA

NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505

G

family with sequence similarity 107, member B

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM107B mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of FAM107B mRNA
Coumestrol results in decreased expression of FAM107B mRNA

NCBI chr17:74,478,608...74,685,027
Ensembl chr17:74,478,608...74,684,989

G

family with sequence similarity 110, member B

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM110B mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of FAM110B mRNA
Coumestrol results in decreased expression of FAM110B mRNA

NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:18,789,389...18,929,828

G

family with sequence similarity 110, member C

decreases expression
multiple interactions

Coumestrol results in decreased expression of FAM110C mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of FAM110C mRNA

NCBI chr 6:47,638,466...47,644,723
Ensembl chr 6:47,638,276...47,644,634

G

FAM111 trypsin like peptidase A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FAM111A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FAM111A mRNA
Coumestrol results in increased expression of FAM111A mRNA

NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547

G

family with sequence similarity 149, member B1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM149B1 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of FAM149B1 mRNA
Coumestrol results in decreased expression of FAM149B1 mRNA

NCBI chr15:3,929,190...3,967,140
Ensembl chr15:3,929,190...3,966,997

G

FAM161 centrosomal protein B

decreases expression
multiple interactions

Coumestrol results in decreased expression of FAM161B mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of FAM161B mRNA

NCBI chr 6:103,990,603...104,007,754
Ensembl chr 6:103,992,170...104,018,776

G

family with sequence similarity 169, member A

decreases expression

Coumestrol results in decreased expression of FAM169A mRNA

NCBI chr 2:28,384,162...28,441,361
Ensembl chr 2:28,383,784...28,438,910

G

family with sequence similarity 171, member B

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of FAM171B mRNA

NCBI chr 3:68,930,755...68,986,113
Ensembl chr 3:68,930,822...68,986,127

G

family with sequence similarity 174, member B

decreases expression

Coumestrol results in decreased expression of FAM174B mRNA

NCBI chr 1:127,515,393...127,618,591
Ensembl chr 1:127,514,041...127,596,128
Ensembl chr 1:127,514,041...127,596,128

G

family with sequence similarity 210, member B

decreases expression

Coumestrol results in decreased expression of FAM210B mRNA

NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397

G

family with sequence similarity 216, member A

increases expression

Coumestrol results in increased expression of FAM216A mRNA

NCBI chr12:34,198,526...34,207,673
Ensembl chr12:34,198,526...34,207,665

G

family with sequence similarity 222, member B

decreases expression

Coumestrol results in decreased expression of FAM222B mRNA

NCBI chr10:62,986,571...63,052,350
Ensembl chr10:62,986,571...63,052,350

G

family with sequence similarity 43, member A

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM43A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of FAM43A mRNA
Coumestrol results in decreased expression of FAM43A mRNA

NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401

G

FA complementation group A

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of FANCA mRNA

NCBI chr19:51,304,126...51,362,586
Ensembl chr19:51,304,021...51,362,527

G

FA complementation group D2

increases expression
multiple interactions

Coumestrol results in increased expression of FANCD2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCD2 mRNA

NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412

G

FA complementation group G

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCG mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCG mRNA
Coumestrol results in increased expression of FANCG mRNA

NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:57,231,685...57,240,029

G

FA complementation group I

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCI mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCI mRNA
Coumestrol results in increased expression of FANCI mRNA

NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640

G

FA complementation group L

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCL mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCL mRNA

NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255

G

phenylalanyl-tRNA synthetase subunit beta

increases expression

Coumestrol results in increased expression of FARSB mRNA

NCBI chr 9:79,887,852...79,947,082
Ensembl chr 9:79,887,842...79,947,045

G

filamin binding LIM protein 1

decreases expression

Coumestrol results in decreased expression of FBLIM1 mRNA

NCBI chr 5:153,883,945...153,915,524
Ensembl chr 5:153,883,960...153,913,757

G

F-box and leucine-rich repeat protein 5

decreases expression

Coumestrol results in decreased expression of FBXL5 mRNA

NCBI chr14:67,305,109...67,347,383
Ensembl chr14:67,267,801...67,347,383

G

F-box protein 38

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FBXO38 mRNA

NCBI chr18:55,956,950...56,004,013
Ensembl chr18:55,956,959...56,003,961

G

F-box protein 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FBXO5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FBXO5 mRNA
Coumestrol results in increased expression of FBXO5 mRNA

NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437

G

Fcf1 rRNA-processing protein

increases expression

Coumestrol results in increased expression of FCF1 mRNA

NCBI chr 6:104,617,780...104,629,643
Ensembl chr 6:104,617,770...104,629,643

G

Fc mu receptor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FCMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA]

PMID:18310284 PMID:19167446

NCBI chr13:42,337,363...42,351,706
Ensembl chr13:42,337,414...42,351,653

G

farnesyl diphosphate farnesyl transferase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FDFT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FDFT1 mRNA
Coumestrol results in increased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of FDPS mRNA
Coumestrol results in increased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

flap structure-specific endonuclease 1

increases expression
multiple interactions

Coumestrol results in increased expression of FEN1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FEN1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FEN1 mRNA

NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003

G

FERM domain containing kindlin 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FERMT2 mRNA

NCBI chr15:18,682,927...18,751,959
Ensembl chr15:18,682,927...18,751,811

G

Fibroblast growth factor receptor 1

decreases expression

Coumestrol results in decreased expression of FGFR1 mRNA

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

fumarate hydratase

increases expression

Coumestrol results in increased expression of FH mRNA

NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266

G

four and a half LIM domains 1

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA]

NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928

G

four and a half LIM domains 2

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of FHL2 mRNA
Coumestrol results in increased expression of FHL2 mRNA

NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192

G

FGF1 intracellular binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIBP mRNA

NCBI chr 1:202,768,065...202,772,405
Ensembl chr 1:202,768,078...202,772,399

G

fidgetin-like 1

increases expression
multiple interactions

Coumestrol results in increased expression of FIGNL1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIGNL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FIGNL1 mRNA

NCBI chr14:86,368,670...86,381,728
Ensembl chr14:86,368,675...86,377,455

G

filamin A interacting protein 1-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FILIP1L mRNA

NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415

G

FIGNL1 interacting regulator of recombination and mitosis

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIRRM mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of FIRRM mRNA
Coumestrol results in increased expression of FIRRM mRNA

NCBI chr13:76,301,914...76,345,842
Ensembl chr13:76,301,918...76,345,804

G

FKBP prolyl isomerase 11

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FKBP11 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of FKBP11 mRNA
Coumestrol results in increased expression of FKBP11 mRNA

NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303

G

FKBP prolyl isomerase 4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FKBP4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FKBP4 mRNA
Coumestrol results in increased expression of FKBP4 mRNA

NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833

G

FKBP prolyl isomerase 5

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of FKBP5 mRNA
Coumestrol results in increased expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

FKBP prolyl isomerase like

increases expression

Coumestrol results in increased expression of FKBPL mRNA

NCBI chr20:4,099,845...4,101,315
Ensembl chr20:4,099,806...4,101,368

G

folliculin

decreases expression
multiple interactions

Coumestrol results in decreased expression of FLCN mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FLCN mRNA

NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769

G

formin-like 2

decreases expression

Coumestrol results in decreased expression of FMNL2 mRNA

NCBI chr 3:37,348,791...37,624,746
Ensembl chr 3:37,348,574...37,624,754

G

formin binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FNBP1 mRNA

NCBI chr 3:14,309,067...14,424,378
Ensembl chr 3:14,309,640...14,424,881

G

formin binding protein 1-like

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FNBP1L mRNA
Coumestrol results in decreased expression of FNBP1L mRNA

NCBI chr 2:210,647,241...210,748,203
Ensembl chr 2:210,647,246...210,738,455

G

fibronectin type III domain containing 3B

decreases expression

Coumestrol results in decreased expression of FNDC3B mRNA

NCBI chr 2:110,311,439...110,617,504
Ensembl chr 2:110,312,694...110,547,830

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box D1

decreases expression

Coumestrol results in decreased expression of FOXD1 mRNA

NCBI chr 2:29,702,558...29,704,978
Ensembl chr 2:29,702,558...29,704,978

G

forkhead box M1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FOXM1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of FOXM1 mRNA
Coumestrol results in increased expression of FOXM1 mRNA

NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684

G

forkhead box O3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOXO3 mRNA
Coumestrol results in decreased expression of FOXO3 mRNA

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

forkhead box P2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOXP2 mRNA

NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683

G

FAD-dependent oxidoreductase domain containing 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of FOXRED2 mRNA

NCBI chr 7:109,521,761...109,538,300
Ensembl chr 7:109,521,761...109,540,874

G

FERM domain containing 3

decreases expression

Coumestrol results in decreased expression of FRMD3 mRNA

NCBI chr 5:87,764,755...88,031,091
Ensembl chr 5:87,764,604...88,031,091

G

FERM domain containing 6

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FRMD6 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of FRMD6 mRNA
Coumestrol results in decreased expression of FRMD6 mRNA

NCBI chr 6:89,345,983...89,419,579
Ensembl chr 6:89,346,035...89,419,579

G

fascin actin-bundling protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FSCN1 mRNA

NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211

G

FtsJ RNA 2'-O-methyltransferase 1

increases expression

Coumestrol results in increased expression of FTSJ1 mRNA

NCBI chr X:14,243,684...14,256,555
Ensembl chr X:14,244,050...14,252,030

G

alpha-L-fucosidase 1

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of FUCA1 mRNA
Coumestrol results in decreased expression of FUCA1 mRNA

NCBI chr 5:148,152,718...148,169,972
Ensembl chr 5:148,152,700...148,169,972

G

Friend virus susceptibility 1

increases expression

Coumestrol results in increased expression of C19ORF48P mRNA

NCBI chr 1:94,730,839...94,736,791
Ensembl chr 1:94,730,606...94,737,594

G

FYN binding protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of FYB2 mRNA

NCBI chr 5:119,677,116...119,800,911
Ensembl chr 5:119,677,204...119,800,910

G

FYVE and coiled-coil domain autophagy adaptor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FYCO1 mRNA
Coumestrol results in decreased expression of FYCO1 mRNA

NCBI chr 8:123,412,105...123,479,315
Ensembl chr 8:123,412,112...123,479,021

G

frizzled class receptor 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of FZD2 mRNA

NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334

G

G2/M-phase specific E3 ubiquitin protein ligase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G2E3 mRNA
Coumestrol results in increased expression of G2E3 mRNA

NCBI chr 6:68,763,847...68,795,305
Ensembl chr 6:68,764,185...68,793,924

G

G3BP stress granule assembly factor 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G3BP2 mRNA

NCBI chr14:15,932,403...16,020,555
Ensembl chr14:15,987,417...16,020,548

G

GA binding protein transcription factor subunit beta 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GABPB2 mRNA
Coumestrol results in increased expression of GABPB2 mRNA

NCBI chr 2:182,755,304...182,795,368
Ensembl chr 2:182,761,359...182,795,109

G

growth arrest and DNA-damage-inducible, alpha

decreases expression
multiple interactions

Coumestrol results in decreased expression of GADD45A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

GADD45G interacting protein 1

increases expression

Coumestrol results in increased expression of GADD45GIP1 mRNA

NCBI chr19:23,320,662...23,323,211
Ensembl chr19:23,320,159...23,323,236

G

galanin and GMAP prepropeptide

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA]

NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959

G

galactosamine (N-acetyl)-6-sulfatase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNS mRNA

NCBI chr19:50,628,639...50,662,477
Ensembl chr19:50,628,552...50,662,246

G

polypeptide N-acetylgalactosaminyltransferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT1 mRNA

NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245

G

polypeptide N-acetylgalactosaminyltransferase 10

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT10 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GALNT10 mRNA
Coumestrol results in decreased expression of GALNT10 mRNA

NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT7 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GALNT7 mRNA
Coumestrol results in decreased expression of GALNT7 mRNA

NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690

G

glucosidase II alpha subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GANAB mRNA

NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695

G

phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase

increases expression

Coumestrol results in increased expression of GART mRNA

NCBI chr11:30,864,896...30,891,125
Ensembl chr11:30,865,889...30,891,125

G

growth arrest-specific 2 like 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GAS2L3 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of GAS2L3 mRNA

NCBI chr 7:23,803,578...23,836,816
Ensembl chr 7:23,806,310...23,836,411

G

GATA binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GATA2 mRNA

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

GATA binding protein 3

decreases expression

Coumestrol results in decreased expression of GATA3 mRNA

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

GATA zinc finger domain containing 1

decreases expression

Coumestrol results in decreased expression of GATAD1 mRNA

NCBI chr 4:30,507,530...30,519,107
Ensembl chr 4:30,507,538...30,519,107

G

guanylate binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GBP2 mRNA

NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571

G

GTP cyclohydrolase I feedback regulator

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GCHFR mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GCHFR mRNA
Coumestrol results in increased expression of GCHFR mRNA

NCBI chr 3:106,158,046...106,162,080
Ensembl chr 3:106,159,394...106,162,080

G

glutamate cysteine ligase, modifier subunit

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

growth differentiation factor 15

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GDF15 mRNA
Coumestrol results in decreased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

glycerophosphodiester phosphodiesterase domain containing 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GDPD3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GDPD3 mRNA
Coumestrol results in decreased expression of GDPD3 mRNA

NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063

G

GTP binding protein overexpressed in skeletal muscle

increases expression

Coumestrol results in increased expression of GEM mRNA

NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:25,214,309...25,225,222

G

gem (nuclear organelle) associated protein 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GEMIN2 mRNA
Coumestrol results in increased expression of GEMIN2 mRNA

NCBI chr 6:76,706,424...76,721,154
Ensembl chr 6:76,707,523...76,721,153

G

gem (nuclear organelle) associated protein 4

increases expression

Coumestrol results in increased expression of GEMIN4 mRNA

NCBI chr10:61,062,420...61,073,529
Ensembl chr10:61,066,425...61,073,431
Ensembl chr10:61,066,425...61,073,431

G

gem (nuclear organelle) associated protein 6

increases expression

Coumestrol results in increased expression of GEMIN6 mRNA

NCBI chr 6:14,786,090...14,790,617
Ensembl chr 6:14,786,070...14,790,612

G

GDNF family receptor alpha 1

increases expression
multiple interactions

Coumestrol results in increased expression of GFRA1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GFRA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GFRA1 mRNA

NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473

G

golgi associated, gamma adaptin ear containing, ARF binding protein 2

increases expression

Coumestrol results in increased expression of GGA2 mRNA

NCBI chr 1:176,552,046...176,585,332
Ensembl chr 1:176,552,046...176,585,361

G

gamma-glutamyl cyclotransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GGCT mRNA

NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277

G

gamma-glutamyl hydrolase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GGH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GGH mRNA
Coumestrol results in increased expression of GGH mRNA

NCBI chr 5:33,529,880...33,552,790
Ensembl chr 5:33,529,880...33,552,787

G

GINS complex subunit 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GINS1 mRNA
Coumestrol results in increased expression of GINS1 mRNA

NCBI chr 3:139,724,513...139,745,930
Ensembl chr 3:139,724,490...139,745,936

G

GINS complex subunit 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GINS2 mRNA
Coumestrol results in increased expression of GINS2 mRNA

NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339

G

GINS complex subunit 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GINS3 mRNA
Coumestrol results in increased expression of GINS3 mRNA

NCBI chr19:9,420,085...9,428,621
Ensembl chr19:9,420,086...9,428,687

G

GINS complex subunit 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS4 mRNA

NCBI chr16:68,787,572...68,799,938
Ensembl chr16:68,767,339...68,802,273

G

galactosidase, alpha

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of GLA mRNA
Coumestrol results in increased expression of GLA mRNA

NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664

G

GLE1 RNA export mediator

increases expression
multiple interactions

Coumestrol results in increased expression of GLE1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GLE1 mRNA

NCBI chr 3:13,209,312...13,237,018
Ensembl chr 3:13,209,322...13,237,379

G

glomulin, FKBP associated protein

increases expression

Coumestrol results in increased expression of GLMN mRNA

NCBI chr14:2,187,144...2,231,295
Ensembl chr14:2,187,642...2,230,420

G

glycosylated lysosomal membrane protein

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of GLMP mRNA

NCBI chr 2:173,794,273...173,797,863
Ensembl chr 2:173,794,255...173,799,960

G

glutaminase

decreases expression

Coumestrol results in decreased expression of GLS mRNA

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

geminin, DNA replication inhibitor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GMNN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GMNN mRNA
Coumestrol results in increased expression of GMNN mRNA

NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054

G

guanine monophosphate synthase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GMPS mRNA

NCBI chr 2:148,441,369...148,491,908
Ensembl chr 2:148,435,643...148,485,875

G

G protein subunit alpha i1

decreases expression

Coumestrol results in decreased expression of GNAI1 mRNA

NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417

G

G protein subunit alpha q

decreases expression

Coumestrol results in decreased expression of GNAQ mRNA

NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672

G

G protein nucleolar 3 like

decreases expression

Coumestrol results in decreased expression of GNL3L mRNA

NCBI chr X:19,961,277...19,994,454
Ensembl chr X:19,958,603...19,994,508

G

glucosamine (N-acetyl)-6-sulfatase

decreases expression

Coumestrol results in decreased expression of GNS mRNA

NCBI chr 7:56,889,148...56,923,173
Ensembl chr 7:56,889,232...56,923,151

G

golgin A2

decreases expression
multiple interactions

Coumestrol results in decreased expression of GOLGA2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GOLGA2 mRNA

NCBI chr 3:15,583,862...15,604,279
Ensembl chr 3:15,584,039...15,604,279

G

glutamic-oxaloacetic transaminase 1

increases expression
multiple interactions

Coumestrol results in increased expression of GOT1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GOT1 mRNA

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glycosylphosphatidylinositol anchor attachment 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPAA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GPAA1 mRNA

NCBI chr 7:108,051,896...108,055,479
Ensembl chr 7:108,051,861...108,055,484

G

glycerol-3-phosphate acyltransferase 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPAT4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GPAT4 mRNA

NCBI chr16:68,819,031...68,852,903
Ensembl chr16:68,819,079...68,852,901

G

G patch domain containing 11

increases expression

Coumestrol results in increased expression of GPATCH11 mRNA

NCBI chr 6:16,229,933...16,243,305
Ensembl chr 6:16,233,059...16,243,238

G

G patch domain containing 2-like

decreases expression

Coumestrol results in decreased expression of GPATCH2L mRNA

NCBI chr 6:105,883,383...105,935,644
Ensembl chr 6:105,883,460...105,934,888

G

G patch domain containing 4

increases expression

Coumestrol results in increased expression of GPATCH4 mRNA

NCBI chr 2:173,499,700...173,520,346
Ensembl chr 2:173,509,897...173,518,684

G

glycerol-3-phosphate dehydrogenase 2

increases expression

Coumestrol results in increased expression of GPD2 mRNA

NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901

G

G protein-coupled estrogen receptor 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of GPER1 mRNA

NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889

G

G protein-coupled receptor 137B

decreases expression

Coumestrol results in decreased expression of GPR137B mRNA

NCBI chr17:86,003,635...86,041,841
Ensembl chr17:85,966,921...86,041,835

G

G protein-coupled receptor 160

decreases expression

Coumestrol results in decreased expression of GPR160 mRNA

NCBI chr 2:112,483,364...112,563,072
Ensembl chr 2:112,484,935...112,563,148

G

G protein-coupled receptor, class C, group 5, member A

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GPRC5A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GPRC5A mRNA
Coumestrol results in decreased expression of GPRC5A mRNA

NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260

G

G protein-coupled receptor, class C, group 5, member C

decreases expression
multiple interactions

Coumestrol results in decreased expression of GPRC5C mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GPRC5C mRNA

NCBI chr10:99,886,900...99,908,928
Ensembl chr10:99,887,077...99,908,926

G

G-protein signaling modulator 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPSM2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GPSM2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA]
Coumestrol results in increased expression of GPSM2 mRNA

PMID:18310284 PMID:19167446

NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154

G

glutathione peroxidase 8

increases expression
multiple interactions

Coumestrol results in increased expression of GPX8 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of GPX8 mRNA

NCBI chr 2:44,676,448...44,680,042
Ensembl chr 2:44,676,454...44,680,195

G

GRAM domain containing 1A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GRAMD1A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GRAMD1A mRNA

NCBI chr 1:86,367,001...86,393,348
Ensembl chr 1:86,367,001...86,393,336

G

growth factor receptor bound protein 10

decreases expression

Coumestrol results in decreased expression of GRB10 mRNA

NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806

G

growth regulating estrogen receptor binding 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GREB1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GREB1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA]
Coumestrol results in increased expression of GREB1 mRNA

PMID:18310284 PMID:19167446 PMID:35307500

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

grainyhead-like transcription factor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GRHL3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GRHL3 mRNA

NCBI chr 5:147,774,161...147,806,291
Ensembl chr 5:147,774,160...147,806,160

G

G protein-coupled receptor kinase 6

increases expression

Coumestrol results in increased expression of GRK6 mRNA

NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644

G

granulin precursor

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of GRN mRNA

NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775

G

GrpE-like 1, mitochondrial

increases expression

Coumestrol results in increased expression of GRPEL1 mRNA

NCBI chr14:74,292,023...74,298,243
Ensembl chr14:74,292,023...74,298,200

G

general transcription factor 2H subunit 4

increases expression

Coumestrol results in increased expression of GTF2H4 mRNA

NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984

G

GTF2I repeat domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GTF2IRD1 mRNA

NCBI chr12:22,254,113...22,361,052
Ensembl chr12:22,254,221...22,361,040

G

G-2 and S-phase expressed 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GTSE1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GTSE1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA]
Coumestrol results in increased expression of GTSE1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806

G

GULP PTB domain containing engulfment adaptor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GULP1 mRNA
Coumestrol results in decreased expression of GULP1 mRNA

NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005

G

H1.2 linker histone, cluster member

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H1-2 mRNA
Coumestrol results in decreased expression of H1-2 mRNA

NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635

G

H2A clustered histone 25

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2AC25 mRNA

NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874

G

H2A.X variant histone

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AX mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of H2AX mRNA
Coumestrol results in increased expression of H2AX mRNA; Coumestrol results in increased expression of H2AX protein modified form

PMID:19167446 PMID:28986287

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2A.Z variant histone 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AZ1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of H2AZ1 mRNA
Coumestrol results in increased expression of H2AZ1 mRNA

NCBI chr 2:226,355,668...226,357,984
Ensembl chr 2:226,355,708...226,358,485

G

H2A.Z variant histone 2

increases expression
multiple interactions

Coumestrol results in increased expression of H2AZ2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AZ2 mRNA

NCBI chr14:81,293,304...81,312,209
Ensembl chr14:81,293,299...81,312,144

G

H2B clustered histone 12

decreases expression

Coumestrol results in decreased expression of H2BC12 mRNA

NCBI chr17:42,485,699...42,486,162

G

H2B clustered histone 6

decreases expression

Coumestrol results in decreased expression of H2BC6 mRNA

NCBI chr17:41,520,775...41,521,238

G

H2B clustered histone 8

decreases expression
multiple interactions

Coumestrol results in decreased expression of H2BC8 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC8 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of H2BC8 mRNA

NCBI chr17:42,708,658...42,709,408

G

H2B clustered histone 9

decreases expression
multiple interactions

Coumestrol results in decreased expression of H2BC9 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC9 mRNA

NCBI chr17:42,470,593...42,478,590

G

H3.3 histone B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H3-3B mRNA

NCBI chr10:101,256,484...101,258,716
Ensembl chr10:101,256,480...101,258,709

G

hydroxyacyl-CoA dehydrogenase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HADH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HADH mRNA
Coumestrol results in increased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

histone H3 associated protein kinase

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of HASPIN mRNA

NCBI chr10:57,747,731...57,750,518
Ensembl chr10:57,747,573...57,750,512

G

histone acetyltransferase 1

increases expression

Coumestrol results in increased expression of HAT1 mRNA

NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517

G

HAUS augmin-like complex, subunit 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HAUS1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HAUS1 mRNA
Coumestrol results in increased expression of HAUS1 mRNA

NCBI chr18:71,275,417...71,286,626
Ensembl chr18:71,273,537...71,286,660

G

HAUS augmin like complex subunit 2

decreases expression

Coumestrol results in decreased expression of HAUS2 mRNA

NCBI chr 3:107,553,146...107,565,982
Ensembl chr 3:107,553,161...107,565,157

G

HAUS augmin-like complex, subunit 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HAUS4 mRNA

NCBI chr15:27,994,530...28,006,147
Ensembl chr15:27,994,532...28,005,938

G

HAUS augmin-like complex, subunit 7

increases expression

Coumestrol results in increased expression of HAUS7 mRNA

NCBI chr X:151,154,979...151,174,441
Ensembl chr X:151,154,979...151,180,577

G

HAUS augmin-like complex, subunit 8

increases expression
multiple interactions

Coumestrol results in increased expression of HAUS8 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of HAUS8 mRNA

NCBI chr16:17,930,819...17,945,254
Ensembl chr16:17,930,820...17,945,237